Document:

Exhibit 4.2

 

EXHIBIT
A

 

NEITHER THESE
SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS.  NOTWITHSTANDING THE
FOREGOING, THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR
OTHER LOAN SECURED BY SUCH SECURITIES.

 

WORLDGATE COMMUNICATIONS, INC.

 

ADDITIONAL INVESTMENT RIGHT

 

	
  Additional Investment Right
  No. [  ]

  	
   

  	
  Dated:  November 30, 2003

  

 

WorldGate
Communications, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, [Name of
Holder] or its registered assigns (the “Holder”),
is entitled to purchase from the Company (a) up to a total of [          ](1) shares of common stock, $0.01
par value per share (the “Common Stock”),
of the Company (each such share, an “Additional
Investment Right Share” and all such shares, the “Additional Investment Right Shares”) at an
exercise price equal to $0.80 per share (as adjusted from time to time as
provided in Section 9, the “Exercise
Price”), and (b) only as part of and in connection with the purchase
of the Additional Investment Right Shares, warrants in the form attached hereto
as Exhibit A to purchase up to [     
](2) shares of Common Stock (including any warrants issued in
replacement or partial exercise thereof, the “Additional Investment Right Warrants”),
at any time and from time to time from and after the date hereof and through
and including the 30th Trading Day following the Effective Date (the “Expiration Date”), and subject to the
following terms and conditions.  This
Additional Investment Right (this “Additional
Investment Right”) is one of a series of similar additional
investment rights issued pursuant to that certain Securities Purchase Agreement,
dated as of the date hereof, by and among the Company and the Purchasers
identified therein (the “Purchase Agreement”).  All such additional investment rights are
referred to herein, collectively, as the “Additional
Investment Rights.”  Common
Stock issuable upon exercise of the Additional Investment Right Warrants shall
be known herein as the “Additional Investment Right Warrant Shares.”  Concurrently with the issuance of Additional
Investment Right Shares to the Holders upon the exercise of this Additional

 

(1)  20% of Common Stock purchased.

(2)  30% warrant coverage on Additional
Investment Right Shares purchased.

 

 

Investment
Right, the Holder shall be issued Additional Investment Right Warrants
exercisable for a number of Additional Investment Right Warrant Shares equal to
30% of the number of Additional Investment Right Shares so issued to the Holder
upon such exercise.

 

1.                                       Definitions.  In addition to the terms defined
elsewhere in this Additional Investment Right, capitalized terms that are not
otherwise defined herein have the meanings given to such terms in the Purchase
Agreement.

 

2.                                       Registration of Additional Investment Right.  The
Company shall register this Additional Investment Right, upon records to be
maintained by the Company for that purpose (the “Additional Investment Right Register”), in the name of the record Holder hereof from time to time.  The Company may deem and treat the
registered Holder of this Additional Investment Right as the absolute owner
hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.

 

3.                                       Registration of Transfers.  The
Company shall register the assignment and transfer of any portion of this
Additional Investment Right in the Additional Investment Right Register, upon
surrender of this Additional Investment Right, with the Form of Assignment
attached hereto duly completed and signed, to the Transfer Agent or to the
Company at its address specified herein. 
Upon any such registration or transfer, a new additional investment
right to purchase Common Stock, in substantially the form of this Additional
Investment Right (any such new additional investment right, a “New Additional Investment Right”), evidencing the portion of this Additional
Investment Right so transferred shall be issued to the transferee and a New
Additional Investment Right evidencing the remaining portion of this Additional
Investment Right not so transferred, if any, shall be issued to the transferring
Holder.  The acceptance of the New
Additional Investment Right by the transferee thereof shall be deemed the
acceptance by such transferee of all of the rights and obligations of a holder
of an Additional Investment Right.

 

4.                                       Exercise and Duration of Additional Investment
Right.

 

(a)                                  This
Additional Investment Right shall be exercisable by the registered Holder at
any time and from time to time on or after the date hereof to and including the
Expiration Date.  At 5:30 P.M., New York
City time on the Expiration Date, the portion of this Additional Investment
Right not exercised prior thereto shall be and become void and of no value.

 

(b)                                 The
Holder may exercise this Additional Investment Right by delivering to the
Company (i) an exercise notice, in the form attached hereto (the “Exercise Notice”), appropriately completed and duly signed,
and (ii) payment of the Exercise Price for the number of Additional
Investment Right Shares and Additional Investment Right Warrants as to which
this Additional Investment Right is being exercised (which may take the form of
a “cashless exercise” if so indicated in the Exercise Notice and if a “cashless
exercise” may occur at such time pursuant to Section 10 below), and the date
such items are delivered to the Company (as determined in accordance with the
notice provisions hereof) is an “Exercise Date.”  The Holder shall not be required to deliver
the original Additional Investment Right in order to effect an exercise
hereunder.  Execution and delivery of
the Exercise Notice shall have the same effect as

 

2

 

cancellation of the original
Additional Investment Right and issuance of a New Additional Investment Right
evidencing the right to purchase the remaining number of Additional Investment
Right Shares and Additional Investment Right Warrants.

 

5.                                       Delivery of Additional Investment Right Shares.

 

(a)                                  Upon
exercise of this Additional Investment Right, the Company shall promptly (but
in no event later than three Trading Days after the Exercise Date) issue or
cause to be issued and cause to be delivered to or upon the written order of
the Holder and in such name or names as the Holder may designate, a certificate
for the Additional Investment Right Shares and Additional Investment Right
Warrants issuable upon such exercise, free of restrictive legends unless a
registration statement covering the resale of the Additional Investment Right
Shares or Additional Investment Right Warrant Shares, respectively, and naming
the Holder as a selling stockholder thereunder is not then effective and the
Additional Investment Right Shares or the Additional Investment Right Warrant
Shares, respectively, are not freely transferable without volume restrictions
pursuant to Rule 144 under the Securities Act. 
The Holder, or any Person so designated by the Holder to receive
Additional Investment Right Shares and Additional Investment Right Warrants,
shall be deemed to have become holder of record of such Additional Investment
Right Shares and Additional Investment Right Warrants as of the Exercise
Date.  The Company shall, upon request
of the Holder, use its best efforts to deliver Additional Investment Right
Shares hereunder electronically through the Depository Trust Corporation or
another established clearing corporation performing similar functions.

 

(b)                                 This
Additional Investment Right is exercisable, either in its entirety or, from
time to time, for a portion of the number of Additional Investment Right Shares
and Additional Investment Right Warrants. 
Upon surrender of this Additional Investment Right following one or more
partial exercises, the Company shall issue or cause to be issued, at its
expense, a New Additional Investment Right evidencing the right to purchase the
remaining number of Additional Investment Right Shares and Additional
Investment Right Warrants.

 

(c)                                  In
addition to any other rights available to a Holder, if the Company fails to
deliver to the Holder a certificate representing Additional Investment Right
Shares by the third Trading Day after the date on which delivery of such
certificate is required by this Additional Investment Right and if after such
third Trading Day the Holder purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a sale by the
Holder of the Additional Investment Right Shares that the Holder anticipated
receiving from the Company (a “Buy-In”), then
the Company shall, within three Trading Days after the Holder’s request and in
the Holder’s discretion, either (i) pay cash to the Holder in an amount equal
to the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to deliver such
certificate (and to issue such Common Stock) shall terminate, or (ii) promptly
honor its obligation to deliver to the Holder a certificate or certificates
representing such Common Stock and pay cash to the Holder in an amount equal to
the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Common Stock, times (B) the Closing Price on the date of the event
giving rise to the Company’s obligation to deliver such certificate.

 

3

 

(d)                                 The
Company’s obligations to issue and deliver Additional Investment Right Shares
and Additional Investment Right Warrants in accordance with the terms hereof
are absolute and unconditional, irrespective of any action or inaction by the
Holder to enforce the same, any waiver or consent with respect to any provision
hereof, the recovery of any judgment against any Person or any action to
enforce the same, or any setoff, counterclaim, recoupment, limitation or
termination, or any breach or alleged breach by the Holder or any other Person
of any obligation to the Company or any violation or alleged violation of law
by the Holder or any other Person, and irrespective of any other circumstance
which might otherwise limit such obligation of the Company to the Holder in connection
with the issuance of Additional Investment Right Shares and Additional
Investment Right Warrants.  Nothing
herein shall limit a Holder’s right to pursue any other remedies available to
it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock upon
exercise of the Additional Investment Right as required pursuant to the terms
hereof.

 

6.                                       Charges, Taxes and Expenses.  
Issuance and delivery of certificates for shares of Common Stock and
Additional Investment Right Warrants upon exercise of this Additional
Investment Right shall be made without charge to the Holder for any issue or transfer
tax, withholding tax, transfer agent fee or other incidental tax or expense in
respect of the issuance of such certificates, all of which taxes and expenses
shall be paid by the Company; provided, however, that the Company shall not be
required to pay any tax which may be payable in respect of any transfer
involved in the registration of any certificates for Additional Investment
Right Shares, Additional Investment Right Warrants or Additional Investment
Rights in a name other than that of the Holder or an Affiliate thereof.  The Holder shall be responsible for all
other tax liability that may arise as a result of holding or transferring this
Additional Investment Right or receiving Additional Investment Right Shares and
Additional Investment Right Warrants upon exercise hereof.

 

7.                                       Replacement of Additional Investment Right.  If this
Additional Investment Right is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and
upon cancellation hereof, or in lieu of and substitution for this Additional
Investment Right, a New Additional Investment Right, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or
destruction and customary and reasonable indemnity, if requested.  Applicants for a New Additional Investment
Right under such circumstances shall also comply with such other reasonable
regulations and procedures and pay such other reasonable third-party costs as
the Company may prescribe.

 

8.                                       Reservation of Additional Investment Right Shares.  The
Company covenants that it will at all times reserve and keep available out of
the aggregate of its authorized but unissued and otherwise unreserved Common
Stock, solely for the purpose of enabling it to issue Additional Investment
Right Shares upon exercise of this Additional Investment Right and Additional
Investment Right Warrant Shares upon exercise of the Additional Investment
Right Warrants as herein provided and as provided in the Additional Investment Right
Warrants, the number of Additional Investment Right Shares which are then
issuable and deliverable upon the exercise of this entire Additional Investment
Right and the number of Additional Investment Right Warrant Shares which are
then issuable and deliverable upon the exercise of any Additional Investment
Right Warrants, free from preemptive rights or any other contingent

 

4

 

purchase
rights of persons other than the Holder (taking into account the adjustments
and restrictions of Section 9). The Company covenants that all
Additional Investment Right Shares and Additional Invesment Right Warrant
Shares so issuable and deliverable shall, upon issuance and the payment of the
applicable Exercise Price in accordance with the terms hereof, or the
Additional Investment Right Warrants, as the case may be, be duly and validly
authorized, issued and fully paid and nonassessable.  The Company will take all such action as may be necessary
to assure that such shares of Common Stock may be issued as provided herein and
further to the Additional Investment Right Warrants without violation of any
applicable law or regulation, or of any requirements of any securities exchange
or automated quotation system upon which the Common Stock may be listed.

 

9.                                       Certain Adjustments.  The
Exercise Price and number of Additional Investment Right Shares issuable upon
exercise of this Additional Investment Right are subject to adjustment from
time to time as set forth in this Section 9.  The exercise price and number of Additional Investment Right
Warrant Shares issuable upon exercise of the Additional Investment Right
Warrants shall be subject to adjustment pursuant to Section 9 of the Additional
Investment Right Warants.

 

(a)                                  Stock
Dividends and Splits.  If the
Company, at any time while this Additional Investment Right is outstanding, (i)
pays a stock dividend on its Common Stock or otherwise makes a distribution on
any class of capital stock that is payable in shares of Common Stock, (ii)
subdivides outstanding shares of Common Stock into a larger number of shares,
or (iii) combines outstanding shares of Common Stock into a smaller number of
shares, then in each such case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock
outstanding immediately before such event and of which the denominator shall be
the number of shares of Common Stock outstanding immediately after such
event.  Any adjustment made pursuant to
clause (i) of this paragraph shall become effective immediately after the
record date for the determination of stockholders entitled to receive such
dividend or distribution, and any adjustment pursuant to clauses (ii) or (iii)
of this paragraph shall become effective immediately after the effective date
of such subdivision or combination.

 

(b)                                 Pro
Rata Distributions.  If the Company,
at any time while this Additional Investment Right is outstanding, distributes
to holders of Common Stock (i) evidences of its indebtedness, (ii) any security
(other than a distribution of Common Stock covered by the preceding paragraph),
(iii) rights or warrants to subscribe for or purchase any security, or
(iv) any other asset (in each case, “Distributed Property”),
then in each such case the Exercise Price in effect immediately prior to the
record date fixed for determination of stockholders entitled to receive such
distribution shall be adjusted (effective on such record date) to equal the
product of such Exercise Price times a fraction of which the denominator shall
be the average of the Closing Prices for the five Trading Days immediately
prior to (but not including) such record date and of which the numerator shall
be such average less the then fair market value of the Distributed Property
distributed in respect of one outstanding share of Common Stock, as determined
by the Company’s independent certified public accountants that regularly
examine the financial statements of the Company (an “Appraiser”).  In such event, the Holder, after receipt of
the determination by the Appraiser, shall have the right to select an
additional appraiser (which shall be a nationally recognized accounting firm),
in which case such fair market value shall be deemed to equal the average of
the values determined by each of the Appraiser and such

 

5

 

appraiser.  As an alternative to the foregoing
adjustment to the Exercise Price, at the request of the Holder delivered before
the 90th day after such record date, the Company will deliver to such Holder,
within five Trading Days after such request (or, if later, on the effective
date of such distribution), the Distributed Property that such Holder would
have been entitled to receive in respect of the Additional Investment Right
Shares for which this Additional Investment Right could have been exercised
immediately prior to such record date. 
If such Distributed Property is not delivered to a Holder pursuant to
the preceding sentence, then upon expiration of or any exercise of the
Additional Investment Right that occurs after such record date, such Holder
shall remain entitled to receive, in addition to the Additional Investment
Right Shares otherwise issuable upon such exercise (if applicable), such
Distributed Property.

 

(c)                                  Fundamental
Transactions.  If, at any time while
this Additional Investment Right is outstanding, (i) the Company effects any
merger or consolidation of the Company with or into another Person, (ii) the
Company effects any sale of all or substantially all of its assets in one or a
series of related transactions, (iii) any tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares for
other securities, cash or property, or (iv) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or
combination of shares of Common Stock covered by Section 9(a) above) (in any
such case, a “Fundamental Transaction”), then
the Holder shall have the right thereafter to receive, upon exercise of this
Additional Investment Right, the same amount and kind of securities, cash or
property as it would have been entitled to receive upon the occurrence of such
Fundamental Transaction if it had been, immediately prior to such Fundamental
Transaction, the holder of the number of Additional Investment Right Shares
then issuable upon exercise in full of this Additional Investment Right (the “Alternate Consideration”). 
The aggregate Exercise Price for this Additional Investment Right will
not be affected by any such Fundamental Transaction, but the Company shall
apportion such aggregate Exercise Price among the Alternate Consideration in a
reasonable manner reflecting the relative value of any different components of
the Alternate Consideration.  If holders
of Common Stock are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then the Holder shall be given the
same choice as to the Alternate Consideration it receives upon any exercise of
this Additional Investment Right following such Fundamental Transaction.  At the Holder’s request, any successor to
the Company or surviving entity in such Fundamental Transaction shall issue to
the Holder a new additional investment right consistent with the foregoing
provisions and evidencing the Holder’s right to purchase the Alternate
Consideration for the aggregate Exercise Price upon exercise thereof.  The terms of any agreement pursuant to which
a Fundamental Transaction is effected shall include terms requiring any such
successor or surviving entity to comply with the provisions of this paragraph
(c) and insuring that the Additional Investment Right (or any such replacement
security) will be similarly adjusted upon any subsequent transaction analogous
to a Fundamental Transaction. If any Fundamental Transaction constitutes or
results in a Change of Control, then at the request of the Holder delivered
before the 90th day after such Fundamental Transaction, the Company (or any
such successor or surviving entity) will purchase the Additional Investment
Right from the Holder for a purchase price, payable in cash within five Trading
Days after such request (or, if later, on the effective date of the

 

6

 

Fundamental Transaction), equal
to the Black Scholes value of the remaining unexercised portion of this
Additional Investment Right on the date of such request.

 

(d)                                 Number
of Additional Investment Right Shares. 
Simultaneously with any adjustment to the Exercise Price pursuant to
paragraphs (a) or (b) of this Section, the number of Additional Investment
Right Shares that may be purchased upon exercise of this Additional Investment
Right shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the increased or
decreased number of Additional Investment Right Shares shall be the same as the
aggregate Exercise Price in effect immediately prior to such adjustment.

 

(e)                                  Calculations.  All calculations under this Section 9
shall be made to the nearest cent or the nearest 1/100th of a share, as
applicable.  The number of shares of
Common Stock outstanding at any given time shall not include shares owned or
held by or for the account of the Company, and the disposition of any such shares
shall be considered an issue or sale of Common Stock.

 

(f)                                    Notice
of Adjustments.  Upon the occurrence
of each adjustment pursuant to this Section 9, the Company at its
expense will promptly compute such adjustment in accordance with the terms of
this Additional Investment Right and prepare a certificate setting forth such
adjustment, including a statement of the adjusted Exercise Price and adjusted
number or type of Additional Investment Right Shares or other securities
issuable upon exercise of this Additional Investment Right (as applicable),
describing the transactions giving rise to such adjustments and showing in
detail the facts upon which such adjustment is based.  Upon written request, the Company will promptly deliver a copy of
each such certificate to the Holder and to the Company’s Transfer Agent.

 

(g)                                 Notice
of Corporate Events.  If the Company
(i) declares a dividend or any other distribution of cash, securities or other
property in respect of its Common Stock, including, without limitation, any
granting of rights or warrants to subscribe for or purchase any capital stock
of the Company or any Subsidiary, (ii) authorizes or approves, enters into any
agreement contemplating or solicits stockholder approval for any Fundamental
Transaction or (iii) authorizes the voluntary dissolution, liquidation or
winding up of the affairs of the Company, then the Company shall deliver to the
Holder a notice describing the material terms and conditions of such
transaction, at least 20 calendar days prior to the applicable record or
effective date on which a Person would need to hold Common Stock in order to
participate in or vote with respect to such transaction, and the Company will
take all steps reasonably necessary in order to insure that the Holder is given
the practical opportunity to exercise this Additional Investment Right prior to
such time so as to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect
therein shall not affect the validity of the corporate action required to be
described in such notice.

 

10.                                 Payment of Exercise Price.  The
Holder shall pay the Exercise Price in immediately available funds; provided,
however, if the Registration Statement did not become effective on or before
Required Effectiveness Date and is not continuously effective through the
Expiration Date, the Holder may satisfy its obligation to pay the Exercise
Price through a

 

7

 

“cashless exercise,” in which
event the Company shall issue to the Holder the number of Additional Investment
Right Shares determined as follows:

 

	
   

  	
   

  	
  X = Y [(A-B)/A]

  
	
  where:

  	
   

  	
   

  
	
   

  	
   

  	
  X = the number of Additional
  Investment Right Shares to be issued to the Holder.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Y = the number of Additional
  Investment Right Shares with respect to which this Additional Investment
  Right is being exercised.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  A = the average of the
  Closing Prices for the five Trading Days immediately prior to (but not
  including) the Exercise Date.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  B = the Exercise Price.

  

 

For purposes
of Rule 144 promulgated under the Securities Act, it is intended, understood
and acknowledged that the Additional Investment Right Shares issued in a
cashless exercise transaction shall be deemed to have been acquired by the
Holder, and the holding period for the Additional Investment Right Shares shall
be deemed to have commenced, on the date this Additional Investment Right was
originally issued pursuant to the Purchase Agreement.

 

11.                                 Limitation on
Exercise.

 

(a)                                  Notwithstanding
anything to the contrary contained herein, the number of shares of Common Stock
that may be acquired by the Holder upon any exercise of this Additional
Investment Right (or otherwise in respect hereof) shall be limited to the
extent necessary to insure that, following such exercise (or other issuance),
the total number of shares of Common Stock then beneficially owned by such
Holder and its Affiliates and any other Persons whose beneficial ownership of
Common Stock would be aggregated with the Holder’s for purposes of Section
13(d) of the Exchange Act, does not exceed 4.999% (the “Maximum
Percentage”) of the total number of issued and outstanding shares of
Common Stock (including for such purpose the shares of Common Stock issuable
upon such exercise).  For such purposes,
beneficial ownership shall be determined in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder.  Each delivery of an Exercise Notice
hereunder will constitute a representation by the Holder that it has evaluated
the limitation set forth in this paragraph and determined that issuance of the
full number of Additional Investment Right Shares requested in such Exercise
Notice is permitted under this paragraph. 
The Company’s obligation to issue shares of Common Stock in excess of
the limitation referred to in this Section shall be suspended (and shall not
terminate or expire notwithstanding any contrary provisions hereof) until such
time, if any, as such shares of Common Stock may be issued in compliance with
such limitation.  By written notice to
the Company, the Holder may waive the provisions of this Section or increase or
decrease the Maximum Percentage to any other percentage specified in such
notice, but (i) any such waiver or increase will not be effective until the
61st day after such notice is delivered to the Company, and (ii) any such
waiver or increase

 

8

 

or decrease will apply only to
the Holder and not to any other holder of Additional Investment Rights.

 

(b)                                 Notwithstanding
anything to the contrary contained herein, the maximum number of shares of
Common Stock that the Company may issue pursuant to the Transaction Documents
at an effective purchase price less than the Closing Price on the Trading Day
immediately preceding the Closing Date shall equal 19.99% of the shares of
Common Stock outstanding on the Closing Date (the “Issuable Maximum”), unless the Company obtains the necessary
stockholder approvals required by the rules and regulations of the Trading
Market.  If, at the time any Holder
requests an exercise of any of the Additional Investment Rights, the Actual
Minimum (excluding any shares issued or issuable at an effective purchase price
in excess of the Closing Price on the Trading Day immediately preceding the
Closing Date) exceeds the Issuable Maximum (and if the Company has not
previously obtained the required stockholder approval), then the Company shall
issue to the Holder requesting such exercise a number of shares of Common Stock
not exceeding such Holder’s pro-rata portion of the Issuable Maximum (based on
such Holder’s share (vis-à-vis other Holders) of the aggregate purchase price
paid under the Purchase Agreement and taking into account any Additional Investment
Right Shares previously issued to such Holder).  For the purposes hereof, “Actual Minimum”
shall mean, as of any date, the maximum aggregate number of shares of Common
Stock then issued or potentially issuable in the future pursuant to the
Transaction Documents, including any Underlying Shares issuable upon exercise
in full of all Additional Investment Rights, ignoring any limits on the number
of shares of Common Stock that may be owned by a Holder at any one time.

 

12.                                 Fractional Shares.  The
Company shall not be required to issue or cause to be issued fractional
Additional Investment Right Shares or Additional Investment Right Warrants to
purchase fractional Additional Investment Right Warrant Shares on the exercise
of this Additional Investment Right.  If
any fraction of a Additional Investment Right Share or if any Additional
Investment Right Warrant to purchase a fraction of an Additional Investment
Right Warrant Share would, except for the provisions of this Section, be
issuable upon exercise of this Additional Investment Right, the number of
Additional Investment Right Shares and/or Additional Investment Right Warrant
Shares issuable upon exercise of the Additional Investment Right Warrants, as
the case may be, to be issued will be rounded up to the nearest whole share.

 

13.                                 Notices.  Any and all notices or other
communications or deliveries hereunder (including without limitation any
Exercise Notice) shall be in writing and shall be deemed given and effective on
the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in this Section
prior to 5:30 p.m. (New York City time) on a Trading Day, (ii) the next Trading
Day after the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile number specified in this Section on a
day that is not a Trading Day or later than 5:30 p.m. (New York City time) on
any Trading Day, (iii) the Trading Day following the date of deposit with a
nationally recognized overnight courier service, or (iv) upon actual receipt by
the party to whom such notice is required to be given.  The address and facsimile numbers for such
notices or communications shall be as set forth in the Purchase Agreement.

 

9

 

14.                                 Additional Investment Right Agent.  The
Company shall serve as additional investment right agent under this Additional
Investment Right.  Upon 30 days’ notice
to the Holder, the Company may appoint a new additional investment right
agent.  Any corporation into which the
Company or any new additional investment right agent may be merged or any
corporation resulting from any consolidation to which the Company or any new
additional investment right agent shall be a party or any corporation to which
the Company or any new additional investment right agent transfers
substantially all of its corporate trust or stockholders services business
shall be a successor additional investment right agent under this Additional Investment
Right without any further act.  Any such
successor additional investment right agent shall promptly cause notice of its
succession as additional investment right agent to be mailed (by first class
mail, postage prepaid) to the Holder at the Holder’s last address as shown on
the Additional Investment Right Register.

 

15.                                 Miscellaneous.

 

(a)                                  Subject
to the restrictions on transfer set forth on the first page hereof, this
Additional Investment Right may be assigned by the Holder.  This Additional Investment Right may not be
assigned by the Company except to a successor in the event of a Fundamental
Transaction.  This Additional Investment
Right shall be binding on and inure to the benefit of the parties hereto and
their respective successors and assigns. 
Subject to the preceding sentence, nothing in this Additional Investment
Right shall be construed to give to any Person other than the Company and the
Holder any legal or equitable right, remedy or cause of action under this
Additional Investment Right.  This
Additional Investment Right may be amended only in writing signed by the
Company and the Holder and their successors and assigns.

 

(b)                                 The
Company will not, by amendment of its governing documents or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Additional Investment
Right, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Holder against
impairment.  Without limiting the
generality of the foregoing, the Company (i) will not increase the par value of
any Additional Investment Right Shares or Additional Investment Right Warrant
Shares above the amount payable therefor on such exercise, (ii) will take all
such action as may be reasonably necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable Additional
Investment Right Shares or Additional Investment Right Warrant Shares on the
exercise of this Additional Investment Right and Additional Investment Right
Warrants, respectively, and (iii) will not close its stockholder books or
records in any manner which interferes with the timely exercise of this
Additional Investment Right.

 

(c)                                  GOVERNING
LAW; VENUE; WAIVER OF JURY TRIAL. 
ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND
INTERPRETATION OF THIS ADDITIONAL INVESTMENT RIGHT SHALL BE GOVERNED BY AND
CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
YORK.  EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY

 

10

 

OR DISCUSSED HEREIN (INCLUDING
WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND
HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR
PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER.  EACH PARTY HEREBY IRREVOCABLY WAIVES
PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH
SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY
AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT
SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE
THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT
TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.  THE COMPANY HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(d)                                 The
headings herein are for convenience only, do not constitute a part of this
Additional Investment Right and shall not be deemed to limit or affect any of
the provisions hereof.

 

(e)                                  In
case any one or more of the provisions of this Additional Investment Right
shall be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Additional
Investment Right shall not in any way be affected or impaired thereby and the
parties will attempt in good faith to agree upon a valid and enforceable
provision which shall be a commercially reasonable substitute therefor, and
upon so agreeing, shall incorporate such substitute provision in this
Additional Investment Right.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

11

 

IN WITNESS
WHEREOF, the Company has caused this Additional Investment Right to be duly
executed by its authorized officer as of the date first indicated above.

 

	
   

  	
  WORLDGATE COMMUNICATIONS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
						

 

12

 

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder
to exercise the right to purchase shares of Common Stock under the foregoing
Additional Investment Right)

 

To:  Worldgate Communications, Inc.

 

The undersigned is the Holder
of Additional Investment Right No.
          (the “Additional Investment Right”) issued by
Worldgate Communications, Inc., a Delaware corporation (the “Company”). 
Capitalized terms used herein and not otherwise defined have the
respective meanings set forth in the Additional Investment Right.

 

1.                                       The
Additional Investment Right is currently exercisable to purchase a total
of                          
Additional Investment Right Shares and Additional Investment Right Warrants
exercisable
for               
shares of Additional Investment Right Shares.

 

2.                                       The
undersigned Holder hereby exercises its right to
purchase                                   
Additional Investment Right Shares and Additional Investment Right Warrants
exercisable
for                
shares of Additional Investment Right Shares (which number of shares underlying
such Additional Investment Right Warrants shall be equal to 30% of the
Additional Investment Right Shares so issued upon exercise of the Additional
Investment Right) in accordance with the terms of the Additional Investment
Right.

 

3.                                       The
Holder intends that payment of the Exercise Price shall be made as (check one):

 

o                                    “Cash
Exercise”

 

o                                    “Cashless
Exercise” (under Section 10)

 

4.                                       If
the holder has elected a Cash Exercise, the holder shall pay the sum of
$                      
to the Company in accordance with the terms of the Additional Investment Right.

 

5.                                       Pursuant
to this exercise, the Company shall deliver to the
holder                         
Additional Investment Right Shares and Additional Investment Right Warrants
exercisable
for              
shares of Additional Investment Right Shares (which number of shares underlying
such Additional Investment Right Warrants shall be equal to 30% of the
Additional Investment Right Shares so issued upon exercise of the Additional
Investment Right) in accordance with the terms of the Additional Investment
Right.

 

6.                                       Following
this exercise, the Additional Investment Right shall be exercisable to purchase
a total
of                         
Additional Investment Right Shares and Additional Investment Right Warrants
exercisable
for                 
shares of Additional Investment Right Shares (which number of shares underlying
such Additional Investment Right Warrants shall be equal to 30% of the
Additional Investment Right Shares so issued upon exercise of the Additional
Investment Right).

 

 

	
  Dated:

  	
   

  	
  ,

  	
   

  	
   

  	
   

  	
  Name of Holder:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Print)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Signature must conform in
  all respects to name of holder as specified on the face of the Additional
  Investment Right)

  
											

 

 

FORM OF ASSIGNMENT

 

[To be
completed and signed only upon transfer of Additional Investment Right]

 

FOR VALUE
RECEIVED, the undersigned hereby sells, assigns and transfers unto
                                                              
the right represented by the within Additional Investment Right to purchase
                         
shares of Common Stock and warrants to purchase shares of Common Stock (which
number of shares underlying such warrants shall be equal to 30% of the shares
so issued upon exercise of the Additional Investment Right) in accordance with
the terms of the Additional Investment Right.of Worldgate Communications, Inc.
to which the within Additional Investment Right relates and appoints
                              
attorney to transfer said right on the books of Worldgate Communications, Inc.
with full power of substitution in the premises.

 

	
  Dated:

  	
   

  	
  ,

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Signature must conform in
  all respects to name of holder as specified on the face of the Additional
  Investment Right)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Address of Transferee

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  In the presence of:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
									

 

 

EXHIBIT
A

 

NEITHER THESE
SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.  THESE SECURITIES AND THE
SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH
SECURITIES.

 

WORLDGATE COMMUNICATIONS, INC.

 

ADDITIONAL INVESTMENT RIGHT WARRANT

 

	
  Additional Investment Right
  Warrant No. [  ]

  	
   

  	
  Dated:  November 28, 2003

  

 

WorldGate
Communications, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, [Name of
Holder] or its registered assigns (the “Holder”),
is entitled to purchase from the Company up to a total of [          ](1) shares of common stock, $0.01
par value per share (the “Common Stock”),
of the Company (each such share, a “Additional
Investment Right Warrant Share” and all such shares, the “Additional Investment Right Warrant Shares”)
at an exercise price equal to $1.00 per share (as adjusted from time to time as
provided in Section 9, the “Exercise
Price”), at any time and from time to time from and after the date
hereof and through and including the date that is five years from the date of
issuance hereof (the “Expiration Date”),
and subject to the following terms and conditions.  This Additional Investment Right Warrant (this “Additional Investment Right Warrant”) is
one of a series of similar Additional Investment Right Warrants issued pursuant
to that certain Securities Purchase Agreement, dated as of the date hereof, by
and among the Company and the Purchasers identified therein (the “Purchase Agreement”).  All such Additional Investment Right
Warrants are referred to herein, collectively, as the “Additional Investment Right Warrants.”

 

1.                                       Definitions.  In addition to the terms defined
elsewhere in this Additional Investment Right Warrant, capitalized terms that
are not otherwise defined herein have the meanings given to such terms in the
Purchase Agreement.

 

(1)  30% warrant coverage based on Additional Investment Right Shares
issued pursuant to Additional Investment Right.

 

 

2.                                       Registration of Additional Investment Right
Warrant.  The Company shall register this Additional
Investment Right Warrant, upon records to be maintained by the Company for that
purpose (the “Additional
Investment Right Warrant Register”),
in the name of the record Holder hereof from time to time.  The Company may deem and treat the
registered Holder of this Additional Investment Right Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.

 

3.                                       Registration of Transfers.  The
Company shall register the transfer of any portion of this Additional
Investment Right Warrant in the Additional Investment Right Warrant Register,
upon surrender of this Additional Investment Right Warrant, with the Form of Assignment
attached hereto duly completed and signed, to the Transfer Agent or to the
Company at its address specified herein. 
Upon any such registration or transfer, a new warrant to purchase Common
Stock, in substantially the form of this Additional Investment Right Warrant
(any such new warrant, a “New
Additional Investment Right Warrant”), evidencing the portion of this Additional Investment Right Warrant so
transferred shall be issued to the transferee and a New Additional Investment
Right Warrant evidencing the remaining portion of this Additional Investment
Right Warrant not so transferred, if any, shall be issued to the transferring
Holder.  The acceptance of the New
Additional Investment Right Warrant by the transferee thereof shall be deemed
the acceptance by such transferee of all of the rights and obligations of a
holder of a Additional Investment Right Warrant.

 

4.                                       Exercise and Duration of Additional Investment
Right Warrants.

 

(a)                                  This
Additional Investment Right Warrant shall be exercisable by the registered
Holder at any time and from time to time on or after the date hereof to and
including the Expiration Date.  At 5:30
P.M., New York City time on the Expiration Date, the portion of this Additional
Investment Right Warrant not exercised prior thereto shall be and become void
and of no value; provided that, if the average of the Closing Prices for the
five Trading Days immediately prior to (but not including) the Expiration Date
exceeds the Exercise Price on the Expiration Date, then this Additional
Investment Right Warrant shall be deemed to have been exercised in full (to the
extent not previously exercised) on a “cashless exercise” basis at 5:30 P.M.
New York City time on the Expiration Date if a “cashless exercise” may occur at
such time pursuant to Section 10 below. 
Notwithstanding anything to the contrary herein, the Expiration Date
shall be extended for each day following the Effective Date that the
Registration Statement is not effective.

 

(b)                                 A
Holder may exercise this Additional Investment Right Warrant by delivering to
the Company (i) an exercise notice, in the form attached hereto (the “Exercise Notice”), appropriately completed and duly signed,
and (ii) payment of the Exercise Price for the number of Additional
Investment Right Warrant Shares as to which this Additional Investment Right
Warrant is being exercised (which may take the form of a “cashless exercise” if
so indicated in the Exercise Notice and if a “cashless exercise” may occur at
such time pursuant to Section 10 below), and the date such items are delivered
to the Company (as determined in accordance with the notice provisions hereof)
is an “Exercise Date.”  The Holder shall not be required to deliver
the original Additional Investment Right Warrant in order to effect an exercise
hereunder.  Execution and delivery of
the Exercise Notice shall have the same effect as

 

2

 

cancellation of the original
Additional Investment Right Warrant and issuance of a New Additional Investment
Right Warrant evidencing the right to purchase the remaining number of
Additional Investment Right Warrant Shares.

 

5.                                       Delivery of Additional Investment Right Warrant
Shares.

 

(a)                                  Upon
exercise of this Additional Investment Right Warrant, the Company shall
promptly (but in no event later than three Trading Days after the Exercise
Date) issue or cause to be issued and cause to be delivered to or upon the
written order of the Holder and in such name or names as the Holder may
designate, a certificate for the Additional Investment Right Warrant Shares
issuable upon such exercise, free of restrictive legends unless a registration
statement covering the resale of the Additional Investment Right Warrant Shares
and naming the Holder as a selling stockholder thereunder is not then effective
and the Additional Investment Right Warrant Shares are not freely transferable
without volume restrictions pursuant to Rule 144 under the Securities Act.  The Holder, or any Person so designated by
the Holder to receive Additional Investment Right Warrant Shares, shall be
deemed to have become holder of record of such Additional Investment Right
Warrant Shares as of the Exercise Date. 
The Company shall, upon request of the Holder, use its best efforts to
deliver Additional Investment Right Warrant Shares hereunder electronically
through the Depository Trust Corporation or another established clearing
corporation performing similar functions.

 

(b)                                 This
Additional Investment Right Warrant is exercisable, either in its entirety or,
from time to time, for a portion of the number of Additional Investment Right
Warrant Shares.  Upon surrender of this
Additional Investment Right Warrant following one or more partial exercises,
the Company shall issue or cause to be issued, at its expense, a New Additional
Investment Right Warrant evidencing the right to purchase the remaining number
of Additional Investment Right Warrant Shares.

 

(c)                                  In
addition to any other rights available to a Holder, if the Company fails to
deliver to the Holder a certificate representing Additional Investment Right
Warrant Shares by the third Trading Day after the date on which delivery of
such certificate is required by this Additional Investment Right Warrant, and
if after such third Trading Day the Holder purchases (in an open market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of
a sale by the Holder of the Additional Investment Right Warrant Shares that the
Holder anticipated receiving from the Company (a “Buy-In”),
then the Company shall, within three Trading Days after the Holder’s request
and in the Holder’s discretion, either (i) pay cash to the Holder in an amount
equal to the Holder’s total purchase price (including brokerage commissions, if
any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to deliver such
certificate (and to issue such Common Stock) shall terminate, or (ii) promptly
honor its obligation to deliver to the Holder a certificate or certificates
representing such Common Stock and pay cash to the Holder in an amount equal to
the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Common Stock, times (B) the Closing Price on the date of the event
giving rise to the Company’s obligation to deliver such certificate.

 

(d)                                 The
Company’s obligations to issue and deliver Additional Investment Right Warrant
Shares in accordance with the terms hereof are absolute and unconditional,

 

3

 

irrespective of any action or
inaction by the Holder to enforce the same, any waiver or consent with respect
to any provision hereof, the recovery of any judgment against any Person or any
action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation
of law by the Holder or any other Person, and irrespective of any other
circumstance which might otherwise limit such obligation of the Company to the
Holder in connection with the issuance of Additional Investment Right Warrant
Shares.  Nothing herein shall limit a
Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company’s failure to timely
deliver certificates representing shares of Common Stock upon exercise of the
Additional Investment Right Warrant as required pursuant to the terms hereof.

 

6.                                       Charges, Taxes and Expenses.  
Issuance and delivery of certificates for shares of Common Stock upon
exercise of this Additional Investment Right Warrant shall be made without
charge to the Holder for any issue or transfer tax, withholding tax, transfer
agent fee or other incidental tax or expense in respect of the issuance of such
certificates, all of which taxes and expenses shall be paid by the Company;
provided, however, that the Company shall not be required to pay any tax which
may be payable in respect of any transfer involved in the registration of any
certificates for Additional Investment Right Warrant Shares or Additional
Investment Right Warrants in a name other than that of the Holder or an Affiliate
thereof.  The Holder shall be
responsible for all other tax liability that may arise as a result of holding
or transferring this Additional Investment Right Warrant or receiving
Additional Investment Right Warrant Shares upon exercise hereof.

 

7.                                       Replacement of Additional Investment Right Warrant.  If this
Additional Investment Right Warrant is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for
and upon cancellation hereof, or in lieu of and substitution for this
Additional Investment Right Warrant, a New Additional Investment Right Warrant,
but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction and customary and reasonable bond or indemnity,
if requested.  Applicants for a New
Additional Investment Right Warrant under such circumstances shall also comply
with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe.

 

8.                                       Reservation of Additional Investment Right Warrant
Shares.  The Company covenants that it will at all times reserve and keep
available out of the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to issue
Additional Investment Right Warrant Shares upon exercise of this Additional
Investment Right Warrant as herein provided, the number of Additional
Investment Right Warrant Shares which are then issuable and deliverable upon
the exercise of this entire Additional Investment Right Warrant, free from
preemptive rights or any other contingent purchase rights of persons other than
the Holder (after giving effect to the adjustments and restrictions of Section
9, if any). The Company covenants that all Additional Investment Right
Warrant Shares so issuable and deliverable shall, upon issuance and the payment
of the applicable Exercise Price in accordance with the terms hereof, be duly
and validly authorized, issued and fully paid and nonassessable.  The Company will take all such action as may be necessary
to assure that such shares of

 

4

 

Common Stock may be
issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated
quotation system upon which the Common Stock may be listed.

 

9.                                       Certain Adjustments.  The
Exercise Price and number of Additional Investment Right Warrant Shares
issuable upon exercise of this Additional Investment Right Warrant are subject
to adjustment from time to time as set forth in this Section 9.

 

(a)                                  Stock
Dividends and Splits.  If the
Company, at any time while this Additional Investment Right Warrant is
outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a
distribution on any class of capital stock that is payable in shares of Common
Stock, (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, or (iii) combines outstanding shares of Common Stock into a smaller
number of shares, then in each such case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common
Stock outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such
event.  Any adjustment made pursuant to
clause (i) of this paragraph shall become effective immediately after the
record date for the determination of stockholders entitled to receive such
dividend or distribution, and any adjustment pursuant to clause (ii) or (iii)
of this paragraph shall become effective immediately after the effective date
of such subdivision or combination.

 

(b)                                 Pro
Rata Distributions.  If the Company,
at any time while this Additional Investment Right Warrant is outstanding,
distributes to holders of Common Stock (i) evidences of its indebtedness, (ii)
any security (other than a distribution of Common Stock covered by the
preceding paragraph), (iii) rights or warrants to subscribe for or
purchase any security, or (iv) any other asset (in each case, “Distributed Property”), then in each such case the Exercise
Price in effect immediately prior to the record date fixed for determination of
stockholders entitled to receive such distribution shall be adjusted (effective
on such record date) to equal the product of such Exercise Price times a
fraction of which the denominator shall be the average of the Closing Prices
for the five Trading Days immediately prior to (but not including) such record
date and of which the numerator shall be such average less the then fair market
value of the Distributed Property distributed in respect of one outstanding
share of Common Stock, as determined by the Company’s independent certified
public accountants that regularly examine the financial statements of the
Company, (an “Appraiser”).  In such event, the Holder, after receipt of
the determination by the Appraiser, shall have the right to select an
additional appraiser (which shall be a nationally recognized accounting firm),
in which case such fair market value shall be deemed to equal the average of
the values determined by each of the Appraiser and such appraiser.  As an alternative to the foregoing
adjustment to the Exercise Price, at the request of the Holder delivered before
the 90th day after such record date, the Company will deliver to such Holder,
within five Trading Days after such request (or, if later, on the effective
date of such distribution), the Distributed Property that such Holder would
have been entitled to receive in respect of the Additional Investment Right
Warrant Shares for which this Additional Investment Right Warrant could have
been exercised immediately prior to such record date.  If such Distributed Property is not delivered to a Holder
pursuant to the preceding sentence, then upon expiration of or any exercise of
the Additional Investment Right Warrant that occurs after such record date,
such Holder shall remain entitled to receive, in addition to the Additional
Investment

 

5

 

Right Warrant Shares otherwise
issuable upon such exercise (if applicable), such Distributed Property.

 

(c)                                  Fundamental
Transactions.  If, at any time while
this Additional Investment Right Warrant is outstanding, (i) the Company
effects any merger or consolidation of the Company with or into another Person,
(ii) the Company effects any sale of all or substantially all of its assets in
one or a series of related transactions, (iii) any tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares for
other securities, cash or property, or (iv) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the
Common Stock is effectively converted into or exchanged for other securities,
cash or property (other than as a result of a subdivision or combination of
shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then the Holder shall have the
right thereafter to receive, upon exercise of this Additional Investment Right
Warrant, the same amount and kind of securities, cash or property as it would
have been entitled to receive upon the occurrence of such Fundamental
Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Additional Investment Right Warrant Shares then
issuable upon exercise in full of this Additional Investment Right Warrant (the
“Alternate Consideration”).  The aggregate Exercise Price for this
Additional Investment Right Warrant will not be affected by any such
Fundamental Transaction, but the Company shall apportion such aggregate
Exercise Price among the Alternate Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternate
Consideration.  If holders of Common
Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this
Additional Investment Right Warrant following such Fundamental Transaction.  At the Holder’s request, any successor to
the Company or surviving entity in such Fundamental Transaction shall issue to
the Holder a new Additional Investment Right Warrant consistent with the
foregoing provisions and evidencing the Holder’s right to purchase the
Alternate Consideration for the aggregate Exercise Price upon exercise
thereof.  The terms of any agreement
pursuant to which a Fundamental Transaction is effected shall include terms
requiring any such successor or surviving entity to comply with the provisions
of this paragraph (c) and insuring that the Additional Investment Right Warrant
(or any such replacement security) will be similarly adjusted upon any
subsequent transaction analogous to a Fundamental Transaction. If any
Fundamental Transaction constitutes or results in a Change of Control, then at
the request of the Holder delivered before the 90th day after such Fundamental
Transaction, the Company (or any such successor or surviving entity) will
purchase the Additional Investment Right Warrant from the Holder for a purchase
price, payable in cash within five Trading Days after such request (or, if
later, on the effective date of the Fundamental Transaction), equal to the
Black-Scholes value of the remaining unexercised portion of this Additional
Investment Right Warrant on the date of such request.

 

(d)                                 Subsequent
Equity Sales.

 

(i)                                     If,
at any time while this Additional Investment Right Warrant is outstanding, the
Company or any Subsidiary issues additional shares of Common Stock or rights, Additional
Investment Right Warrants, options or other securities or debt

 

6

 

convertible, exercisable or exchangeable for
shares of Common Stock or otherwise entitling any Person to acquire shares of
Common Stock (collectively, “Common Stock
Equivalents”) at an effective net price to the Company per share of
Common Stock (the “Effective Price”)
less than the Exercise Price (as adjusted hereunder to such date), then the
Exercise Price shall be reduced to equal the lesser of (x) 125% of the
Effective Price and (x) the Exercise Price. 
If, at any time while this Additional Investment Right Warrant is
outstanding, the Company or any Subsidiary issues Common Stock or Common Stock
Equivalents at an Effective Price greater than the Exercise Price (as adjusted
hereunder to such date) but less than the average Closing Price over the five
Business Days prior to such issuance (the “Adjustment Price”),
then the Exercise Price shall be reduced to equal the product of (A) the
Exercise Price in effect immediately prior to such issuance of Common Stock or
Common Stock Equivalents times (B) a fraction, the numerator of which is the
sum of (1) the number of shares of Common Stock outstanding immediately prior
to such issuance, plus (2) the number of shares of Common Stock which the
aggregate Effective Price of the Common Stock issued (or deemed to be issued)
would purchase at the Adjustment Price, and the denominator of which is the
aggregate number of shares of Common Stock outstanding or deemed to be
outstanding immediately after such issuance. 
For purposes of this paragraph, in connection with any issuance of any
Common Stock Equivalents, (A) the maximum number of shares of Common Stock
potentially issuable at any time upon conversion, exercise or exchange of such
Common Stock Equivalents (the “Deemed Number”)
shall be deemed to be outstanding upon issuance of such Common Stock
Equivalents, (B) the Effective Price applicable to such Common Stock shall
equal the weighted average dollar value of consideration payable to the Company
to purchase such Common Stock Equivalents and to convert, exercise or exchange
them into Common Stock (net of any discounts, fees, commissions and other
expenses), divided by the Deemed Number, and (C) no further adjustment shall be
made to the Exercise Price upon the actual issuance of Common Stock upon
conversion, exercise or exchange of such Common Stock Equivalents.

 

(ii)                                  If,
at any time while this Additional Investment Right Warrant is outstanding, the
Company or any Subsidiary issues Common Stock Equivalents with an Effective
Price or a number of underlying shares that floats or resets or otherwise
varies or is subject to adjustment based (directly or indirectly) on market
prices of the Common Stock (a “Floating Price Security”),
then for purposes of applying the preceding paragraph in connection with any
subsequent exercise, the Effective Price will be determined separately on each
Exercise Date and will be deemed to equal the lowest Effective Price at which
any holder of such Floating Price Security is entitled to acquire Common Stock
on such Exercise Date (regardless of whether any such holder actually acquires
any shares on such date).

 

(iii)                               Notwithstanding
the foregoing, no adjustment will be made under this paragraph (d) in respect
to any issuance of Common Stock or Common Stock Equivalents (A) upon exercise
or conversion of any options or other securities described in Schedule 3.1(f)
of the Purchase Agreement (provided that such exercise or conversion occurs in
accordance with the terms thereof, without amendment or modification, and that
the applicable exercise or conversion price or ratio is described in such
schedule) or

 

7

 

otherwise pursuant to any employee benefit
plan described in the SEC Reports, Schedule 3.1(f) of the Purchase Agreement or
hereafter adopted by the Company and approved by its stockholders, (B) in
connection with any grant of options to employees, officers, directors or consultants
of the Company pursuant to a stock option plan duly adopted by the Company’s
board of directors or in respect of the issuance of Common Stock upon exercise
of any such options, or (C) the issuance of securities, in connection with a
joint venture or development agreement or strategic partnership, or similar
agreement approved by the Company’s board of directors, a primary purpose of
which is not to raise equity capital and to an entity whose primary business is
other than investing in other entities.

 

(e)                                  Number
of Additional Investment Right Warrant Shares.  Simultaneously with any adjustment to the Exercise Price pursuant
to paragraphs (a) or (b) of this Section, the number of Additional Investment
Right Warrant Shares that may be purchased upon exercise of this Additional
Investment Right Warrant shall be increased or decreased proportionately, so
that after such adjustment the aggregate Exercise Price payable hereunder for
the increased or decreased number of Additional Investment Right Warrant Shares
shall be the same as the aggregate Exercise Price in effect immediately prior
to such adjustment.

 

(f)                                    Calculations.  All calculations under this Section 9
shall be made to the nearest cent or the nearest 1/100th of a share, as
applicable.  The number of shares of
Common Stock outstanding at any given time shall not include shares owned or
held by or for the account of the Company, and the disposition of any such
shares shall be considered an issue or sale of Common Stock.

 

(g)                                 Notice
of Adjustments.  Upon the occurrence
of each adjustment pursuant to this Section 9, the Company at its
expense will promptly compute such adjustment in accordance with the terms of
this Additional Investment Right Warrant and prepare a certificate setting
forth such adjustment, including a statement of the adjusted Exercise Price and
adjusted number or type of Additional Investment Right Warrant Shares or other
securities issuable upon exercise of this Additional Investment Right Warrant
(as applicable), describing the transactions giving rise to such adjustments
and showing in detail the facts upon which such adjustment is based.  Upon written request, the Company will
promptly deliver a copy of each such certificate to the Holder and to the
Company’s Transfer Agent.

 

(h)                                 Notice
of Corporate Events.  If the Company
(i) declares a dividend or any other distribution of cash, securities or other
property in respect of its Common Stock, including without limitation any
granting of rights or warrants to subscribe for or purchase any capital stock
of the Company or any Subsidiary, (ii) authorizes or approves, enters into any
agreement contemplating or solicits stockholder approval for any Fundamental
Transaction or (iii) authorizes the voluntary dissolution, liquidation or
winding up of the affairs of the Company, then the Company shall deliver to the
Holder a notice describing the material terms and conditions of such
transaction, at least 20 calendar days prior to the applicable record or
effective date on which a Person would need to hold Common Stock in order to
participate in or vote with respect to such transaction, and the Company will
take all steps reasonably necessary in order to insure that the Holder is given
the practical opportunity to exercise this Additional Investment Right Warrant
prior to such time so as to participate in or vote with respect to such
transaction;

 

8

 

provided, however, that the
failure to deliver such notice or any defect therein shall not affect the validity
of the corporate action required to be described in such notice.

 

10.                                 Payment of Exercise Price.  The
Holder shall pay the Exercise Price in immediately available funds; provided,
however, that the Holder may satisfy its obligation to pay the Exercise Price
through a “cashless exercise,” in which event the Company shall issue to the
Holder the number of Additional Investment Right Warrant Shares determined as
follows:

 

	
   

  	
  X = Y [(A-B)/A]

  
	
  where:

  	
   

  
	
   

  	
  X = the number of Additional
  Investment Right Warrant Shares to be issued to the Holder.

  
	
   

  	
   

  
	
   

  	
  Y = the number of Additional
  Investment Right Warrant Shares with respect to which this Additional
  Investment Right Warrant is being exercised.

  
	
   

  	
   

  
	
   

  	
  A = the average of the
  Closing Prices for the five Trading Days immediately prior to (but not
  including) the Exercise Date.

  
	
   

  	
   

  
	
   

  	
  B = the Exercise Price.

  

 

For
purposes of Rule 144 promulgated under the Securities Act, it is intended,
understood and acknowledged that the Additional Investment Right Warrant Shares
issued in a cashless exercise transaction shall be deemed to have been acquired
by the Holder, and the holding period for the Additional Investment Right
Warrant Shares shall be deemed to have commenced, on the date this Additional
Investment Right Warrant was originally issued pursuant to the Purchase
Agreement.

 

11.                                 Limitation on Exercise.

 

(a)                                  Notwithstanding
anything to the contrary contained herein, the number of shares of Common Stock
that may be acquired by the Holder upon any exercise of this Additional Investment
Right Warrant (or otherwise in respect hereof) shall be limited to the extent
necessary to insure that, following such exercise (or other issuance), the
total number of shares of Common Stock then beneficially owned by such Holder
and its Affiliates and any other Persons whose beneficial ownership of Common
Stock would be aggregated with the Holder’s for purposes of Section 13(d) of
the Exchange Act, does not exceed 4.999% (the “Maximum Percentage”) of the total number of issued and
outstanding shares of Common Stock (including for such purpose the shares of
Common Stock issuable upon such exercise). 
For such purposes, beneficial ownership shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder.  The Company
shall, instead of issuing shares of Common Stock in excess of the limitation
referred to in this Section 11,  pay to
such Holder an amount in cash equal to the fair market value, less the Exercise
Price, of the number of shares of Common Stock in excess of such limitation; provided,
however, that the Holder may, at its option, elect to waive the
requirement to deliver such cash and the Company’s obligation to

 

9

 

issue shares in excess of the
foregoing limitation shall be suspended until such time, if any, as such shares
of Common Stock may be issued in compliance with such limitation.  Additionally, by written notice to the
Company, the Holder may waive the provisions of this Section 11 or increase or
decrease the Maximum Percentage to any other percentage specified in such
notice, but (i) any such waiver or increase will not be effective until the
61st day after such notice is delivered to the Company, and (ii) any such
waiver or increase or decrease will apply only to the Holder and not to any
other holder of Additional Investment Right Warrants.

 

(b)                                 Notwithstanding
anything to the contrary contained herein, the maximum number of shares of
Common Stock that the Company may issue pursuant to the Transaction Documents
at an effective purchase price less than the Closing Price on the Trading Day
immediately preceding the Closing Date shall equal 19.99% of the shares of
Common Stock outstanding on the Closing Date (the “Issuable Maximum”), unless
the Company obtains the necessary stockholder approvals required by the rules
and regulations of the Trading Market. 
If, at the time any Holder requests an exercise of any of the Additional
Investment Right Warrants, the Actual Minimum (excluding any shares issued or
issuable at an effective purchase price in excess of the Closing Price on the
Trading Day immediately preceding the Closing Date) exceeds the Issuable
Maximum (and if the Company has not previously obtained the required stockholder
approval), then the Company shall issue to the Holder requesting such exercise
a number of shares of Common Stock not exceeding such Holder’s pro-rata portion
of the Issuable Maximum (based on such Holder’s share (vis-à-vis other Holders)
of the aggregate purchase price paid under the Purchase Agreement and taking
into account any Additional Investment Right Warrant Shares previously issued
to such Holder).  For the purposes
hereof, “Actual Minimum” shall
mean, as of any date, the maximum aggregate number of shares of Common Stock
then issued or potentially issuable in the future pursuant to the Transaction
Documents, including any Underlying Shares issuable upon exercise in full of
all Additional Investment Right Warrants, without giving effect to any limits
on the number of shares of Common Stock that may be owned by a Holder at any
one time.

 

12.                                 Fractional Shares.  The
Company shall not be required to issue or cause to be issued fractional
Additional Investment Right Warrant Shares on the exercise of this Additional
Investment Right Warrant.  If any
fraction of a Additional Investment Right Warrant Share would, except for the
provisions of this Section, be issuable upon exercise of this Additional
Investment Right Warrant, the number of Additional Investment Right Warrant
Shares to be issued will be rounded up to the nearest whole share.

 

13.                                 Notices.  Any and all notices or other
communications or deliveries hereunder (including without limitation any
Exercise Notice) shall be in writing and shall be deemed given and effective on
the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in this Section
prior to 5:30 p.m. (New York City time) on a Trading Day, (ii) the next Trading
Day after the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile number specified in this Section on a
day that is not a Trading Day or later than 5:30 p.m. (New York City time) on
any Trading Day, (iii) the Trading Day following the date of mailing, if sent
by nationally recognized overnight courier service, or (iv) upon actual receipt
by the party to whom such notice is required to be given.  The address for such notices or
communications shall be as set forth in the Purchase Agreement.

 

10

 

14.                                 Additional Investment Right Warrant Agent.  The
Company shall serve as additional investment right warrant agent under this
Additional Investment Right Warrant.  Upon
30 days’ notice to the Holder, the Company may appoint a new additional
investment right warrant agent.  Any
corporation into which the Company or any new Additional Investment Right
Warrant agent may be merged or any corporation resulting from any consolidation
to which the Company or any new additional investment right warrant agent shall
be a party or any corporation to which the Company or any new additional
investment right warrant agent transfers substantially all of its corporate
trust or stockholders services business shall be a successor additional
investment right warrant agent under this Additional Investment Right Warrant
without any further act.  Any such
successor additional investment right warrant agent shall promptly cause notice
of its succession as additional investment right warrant agent to be mailed (by
first class mail, postage prepaid) to the Holder at the Holder’s last address
as shown on the Additional Investment Right Warrant Register.

 

15.                                 Miscellaneous.

 

(a)                                  Subject
to the restrictions on transfer set forth on the first page hereof, this
Additional Investment Right Warrant may be assigned by the Holder.  This Additional Investment Right Warrant may
not be assigned by the Company except to a successor in the event of a Fundamental
Transaction.  This Additional Investment
Right Warrant shall be binding on and inure to the benefit of the parties
hereto and their respective successors and assigns.  Subject to the preceding sentence, nothing in this Additional
Investment Right Warrant shall be construed to give to any Person other than
the Company and the Holder any legal or equitable right, remedy or cause of
action under this Additional Investment Right Warrant.  This Additional Investment Right Warrant may
be amended only in writing signed by the Company and the Holder and their
successors and assigns.

 

(b)                                 The
Company will not, by amendment of its governing documents or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Additional Investment
Right Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Holder against
impairment.  Without limiting the
generality of the foregoing, the Company (i) will not increase the par value of
any Additional Investment Right Warrant Shares above the amount payable
therefor on such exercise, (ii) will take all such action as may be reasonably
necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Additional Investment Right Warrant Shares
on the exercise of this Additional Investment Right Warrant, and (iii) will not
close its stockholder books or records in any manner which interferes with the
timely exercise of this Additional Investment Right Warrant.

 

(c)                                  GOVERNING
LAW; VENUE; WAIVER OF JURY TRIAL. 
ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND
INTERPRETATION OF THIS ADDITIONAL INVESTMENT RIGHT WARRANT SHALL BE GOVERNED BY
AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
YORK.  EACH PARTY HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY

 

11

 

DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN
(INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION
DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY
SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS
IMPROPER.  EACH PARTY HEREBY IRREVOCABLY
WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY
SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY
AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT
SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE
THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT
TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.  THE COMPANY HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(d)                                 The
headings herein are for convenience only, do not constitute a part of this
Additional Investment Right Warrant and shall not be deemed to limit or affect
any of the provisions hereof.

 

(e)                                  In
case any one or more of the provisions of this Additional Investment Right Warrant
shall be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Additional
Investment Right Warrant shall not in any way be affected or impaired thereby
and the parties will attempt in good faith to agree upon a valid and
enforceable provision which shall be a commercially reasonable substitute
therefor, and upon so agreeing, shall incorporate such substitute provision in
this Additional Investment Right Warrant.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

12

 

IN WITNESS
WHEREOF, the Company has caused this Additional Investment Right Warrant to be
duly executed by its authorized officer as of the date first indicated above.

 

	
   

  	
  WORLDGATE COMMUNICATIONS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
						

 

13

 

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder
to exercise the right to purchase shares of Common Stock under the foregoing
Additional Investment Right Warrant)

 

To:  WORLDGATE COMMUNICATIONS, INC.

 

The undersigned is the Holder
of Additional Investment Right Warrant No.
              
(the “Additional Investment Right Warrant”)
issued by Worldgate Communications, Inc., a Delaware corporation (the “Company”). 
Capitalized terms used herein and not otherwise defined have the
respective meanings set forth in the Additional Investment Right Warrant.

 

1.                                       The
Additional Investment Right Warrant is currently exercisable to purchase a
total of
                           
Additional Investment Right Warrant Shares.

 

2.                                       The
undersigned Holder hereby exercises its right to purchase
                                    Additional
Investment Right Warrant Shares pursuant to the Additional Investment Right
Warrant.

 

3.                                       The
Holder intends that payment of the Exercise Price shall be made as (check one):

 

o                                    “Cash
Exercise” under Section 10

 

o                                    “Cashless
Exercise” under Section 10

 

4.                                       If
the holder has elected a Cash Exercise, the holder shall pay the sum of
$                     to
the Company in accordance with the terms of the Additional Investment Right
Warrant.

 

5.                                       Pursuant
to this exercise, the Company shall deliver to the holder
                          Additional
Investment Right Warrant Shares in accordance with the terms of the Additional
Investment Right Warrant.

 

6.                                       Following
this exercise, the Additional Investment Right Warrant shall be exercisable to
purchase a total of
                       Additional
Investment Right Warrant Shares.

 

	
  Dated:

  	
   

  	
  ,

  	
   

  	
   

  	
   

  	
  Name of Holder:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Print)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Signature must conform in
  all respects to name of holder as specified on the face of the Additional
  Investment Right Warrant)

  
											

 

 

FORM OF ASSIGNMENT

 

[To be
completed and signed only upon transfer of Additional Investment Right Warrant]

 

FOR VALUE
RECEIVED, the undersigned hereby sells, assigns and transfers unto
                                                     the
right represented by the within Additional Investment Right Warrant to purchase
                 shares
of Common Stock of Worldgate Communications, Inc. to which the within
Additional Investment Right Warrant relates and appoints
                            
attorney to transfer said right on the books of Worldgate Communications, Inc.
with full power of substitution in the premises.

 

	
  Dated:

  	
   

  	
  ,

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  (Signature must conform in
  all respects to name of holder as specified on the face of the Additional
  Investment Right Warrant)

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Address of Transferee

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  In the presence of:Exhibit 10.1

 

Confidential Materials omitted and filed
separately with the

Securities and Exchange Commission. 
Asterisks denote omissions.

 

 

CONSUMER GENOMICS AND HAPTM  TECHNOLOGY
LICENSE

AGREEMENT

BETWEEN

SCIONA LIMITED

AND

GENAISSANCE PHARMACEUTICALS, INC.

 

 

17 November 2003

 

 

EXECUTION COPY

 

CONSUMER GENOMICS AND HAPTM
TECHNOLOGY LICENSE AGREEMENT

THIS AGREEMENT,
effective as of November 17, 2003 (the “Effective
Date”), between SCIONA LIMITED, a
corporation duly organized and existing under the laws of United Kingdom, and
having its principal place of business at 25 Broadmarsh Business and Innovation
Centre, Harts Farm Way, Havant Hampshire, PO9 1HS, United Kingdom; and GENAISSANCE PHARMACEUTICALS, INC., a corporation duly organized and
existing under the laws of the State of Delaware, and having its principal
place of business at Five Science Park, New Haven, Connecticut 06511.

 

WITNESSETH:

 

WHEREAS, Sciona has
developed a fully integrated solution for providing personalized well-being
advice and formulations based on established genotype-phenotype links; and

 

WHEREAS, Genaissance
has developed a fully integrated solution for connecting genomic variation to
phenotypes, which is known as HAPTM
Technology, and which combines Genaissance’s proprietary HAPTM Database of proprietary gene
polymorphisms, including specific single nucleotide polymorphism (SNPs) and
haplotype markers, known as HAPTM
Markers, the DecoGen® Informatics
System, Genaissance’s dedicated clinical genotyping facilities, and
Genaissance’s genetic association expertise (as such capitalized terms and
other capitalized terms are hereinafter defined); and

 

WHEREAS, Genaissance
is interested in the exploitation of the HAP
Technology for consumer genomics and research projects to identify new genetic
links in the consumer genomics area; and

 

WHEREAS, Sciona and
its Affiliates are interested in obtaining access to the HAP Technology and related genetic
association expertise for use in developing genetic tests containing HAP Markers for use by consumers in
selecting Consumer Products and in making lifestyle choices; and

 

WHEREAS, Sciona is
interested in using Genaissance as its exclusive provider of genotyping
services to support sales of genetic tests containing HAP Markers, and as its preferred provider
of genotyping services to support sales of certain other genetic tests, in each
case in North America and other territories in which Genaissance has an
appropriately qualified laboratory; and

 

WHEREAS, Genaissance
is willing to grant Sciona access to its HAP
Technology, and to provide such genotyping services, as well as certain support
services, all upon the terms and conditions set forth below; and

 

 

WHEREAS, Genaissance
and Sciona also wish to collaborate to discover HAP Marker associations and to sell HAP Marker association delivery services;

 

NOW THEREFORE, in
consideration of the premises and of the covenants herein contained, the
Parties hereto mutually agree as follows:

 

1.                                      DEFINITIONS.

 

1.1                               “Affiliate” shall mean any corporation or
other entity that directly or indirectly controls, is controlled by or is under
common control with a Party.  A
corporation or other entity shall be regarded as in control of another
corporation or entity if it owns or directly or indirectly controls more than
fifty percent (50%) of the outstanding voting stock or other ownership interest
of the other corporation or entity, or if it possesses, directly or indirectly,
the power to manage, direct or cause the direction of the management and
policies of the corporation or other entity or the power to elect or appoint
more than fifty percent (50%) of the members of the governing body of the
corporation or other entity.  Any such
other relationship as in fact results in actual control over the management,
business and affairs of a corporation or other entity shall also be deemed to
constitute control.  Each of Prelude
Trust plc and Abbey National Treasury Services Overseas Holding are expressly
excluded from the definition of Sciona’s “Affiliates”.

 

1.2                               “Agreement” means this document, together
with all Exhibits and Schedules hereto.

 

1.3                               “Confidential Information”  means (a) all proprietary materials,
data, know-how (including Know-How) or other information received by a Party or
its Affiliates from the other Party or its Affiliates in connection with the
performance of this Agreement (and which, in the case of Sciona and its
Affiliates as recipient, shall include the HAP
Database and all information contained therein related to HAP Markers and their associations and the
DecoGen Informatics System), and
(b) all other materials, data, know-how or other information disclosed or
supplied by or on behalf of either Party or its Affiliates and identified as
“Confidential” or “Proprietary.”

 

1.4                               “Consumer Product” shall mean any product
or service, other than a Prescription Product or a Medical Diagnosis Product,
that is directly or indirectly marketed, sold or provided to consumers in a
manner that indicates such product or service is intended for use in a Consumer
Products Market.

 

1.5                               “Consumer Products Market” shall mean
personal, family or household purposes, including over-the-counter medicines,
cosmetics, fragrances, vitamins and supplements, foods, and beverages.

 

1.6                               “Control”
or “Controlled” means with respect to
any Know-How, Patent Right or other intellectual property right, the possession
(whether by license, other than pursuant to this Agreement, or ownership) by a
Party or its Affiliates of the ability to grant to the other Party or its
Affiliates access and/or a license as provided herein without violating the
terms of any

 

2

 

agreement or other arrangement with any Third Party pursuant to which
the relevant Party or its Affiliates derive their right, title or interest in
such intellectual property, and provided that the terms of such Third Party
agreement or arrangement are not entered into for the primary purpose of
avoiding or restricting any liability or obligation arising under this
Agreement.

 

1.7                               “DecoGenâ Informatics System” or “DecoGen Informatics System” shall mean the
system that permits access to the HAP Database and includes the DecoGenâ Data Manager Software and DecoGenâ Browser Software and any associated
user manuals, whether existing on the Effective Date (as described in Exhibit
1.7) or developed by Genaissance during the Access Period and Controlled by
Genaissance.  For the avoidance of
doubt, the DecoGen Informatics System
does not include (a) any source code, or (b) Third Party software that Sciona or
its Affiliates have independently of Genaissance licensed from a Third Party.

 

1.8                               “Dual-Purpose Product” shall mean any
Consumer Product that includes a HAP
Marker Genetic Test that may be used by a Licensed Healthcare Practitioner to
make a medical diagnosis for human subjects.

 

1.9                               “Field of Use” shall mean the (a) discovery
of HAP Marker Associations and
(b) the development, manufacturing, marketing and selling of HAP Marker Genetic Tests, in each case,
solely for use by Sciona, Affiliates of Sciona, and other Permitted Sciona
Partners in the development, manufacturing, marketing and selling of (i)
Consumer Products and (ii) Dual-Purpose Products to the extent that such
products are (or, in the case of products in development or manufacture, are
intended to be) marketed and sold by Sciona and Permitted Sciona Partners
solely as Consumer Products, provided
however, that Genaissance retains the right to enter into Permitted
Third Party Agreements.  The Field of
Use explicitly excludes the use of HAP
Marker Genetic Tests in the discovery, development, manufacture, marketing,
selling or prescribing of Medical Diagnosis Products, Prescription Products,
or, to the extent intended for uses other than as a Consumer Product, Dual
Purpose Products, and is subject to rights granted by Genaissance to Third
Parties under agreements that exist as of the Effective Date and are listed in Exhibit
1.9.

 

1.10                        “First Commercial Sale” shall mean the
first sale for use or consumption by the general public of a Genetic Test in a
country.

 

1.11                        “Genaissance” shall mean Genaissance
Pharmaceuticals, Inc.

 

1.12                        “Genaissance Know-How”  shall mean any Know-How Controlled by
Genaissance as of the Effective Date or during the Access Period, including,
without limitation, any data on the sequence, frequency and distribution of HAP Markers and other information
contained in the HAP Database.

 

1.13                        “Genaissance Patent Rights”  shall mean, individually and
collectively, the HAP Marker
Patent Rights and the HAP Marker
Association Patent Rights.

 

3

 

1.14                        “Genaissance Territory” shall mean any
country or geographic region for which Genaissance operates a laboratory that
meets all material technical requirements reasonably requested by Sciona (or
its Affiliates) for performing the Genetic Tests.

 

1.15                        “Gene” means a nucleic acid sequence
(including allelic variations thereof) that (a) contains the sequence
information for the transcription, translation or amino acid sequence of a
designated protein, and (b) satisfies the criteria set forth in Exhibit 1.17
hereto.

 

1.16                        “Genetic Tests”  shall mean individually and collectively the HAP Marker Genetic Tests and the Sciona
Genetic Tests.

 

1.17                        “HAPÔ Database” or “HAP Database” shall mean Genaissance’s proprietary database
containing annotated data on the sequence, frequency and distribution of
polymorphisms and HAP Markers
discovered from analysis of genetic material contained in the Index Repository,
as more fully described in Exhibit 1.17 hereto.

 

1.18                        “HAPÔ Marker” or “HAP
Marker” shall mean any human polymorphism or human haplotype that is
present in the HAP Database at
any time during the Access Period.  The
term HAP Marker shall not include
any polymorphism or haplotype that is obtained independently by Sciona without
access to the HAP Database or use
of its contents, as evidenced by contemporary written documents.

 

1.19                        “HAP Marker Association” shall mean an
association between a Phenotype and a specific HAP
Marker or combination of HAP
Markers, including associations arising out of the activities described in
Article 3.  The term HAP Marker Association shall not include
any association between a Phenotype and a specific HAP Marker or combination of HAP Markers that is obtained independently by Sciona without
access to the HAP Database or use
of its contents, as evidenced by contemporary written documents.

 

1.20                        “HAP Marker Association Patent Rights”
shall mean Patent Rights claiming any HAP
Marker Association or use thereof.

 

1.21                        “HAP Marker Genetic Test” shall mean a
genetic test that is designed for and intended for use in detecting the
presence or absence of one or more HAP
Markers in a human individual, which test may be designed and intended for
additional uses.

 

1.22                        “HAP Marker Patent Rights” shall mean
Patent Rights claiming any HAP
Markers, combination of HAP Markers
or in each case, use thereof.

 

1.23                        “Healthcare
Practitioner” shall mean any provider of health related advice or
services to humans, including medical doctors, dentists, optometrists,
psychologists, physician assistants, nurses, nurse practitioners, dieticians,
genetic counselors, physical therapists and personal fitness trainers.

 

4

 

1.24                        “Index Repository” means Genaissance’s
proprietary collection of immortalized cell lines established from unrelated
and related individuals from various geographical origins and from members of
extended families.

 

1.25                        “Know-How” shall mean proprietary data,
information, inventions, practices, methods, knowledge, know-how, trade
secrets, processes, formulas, assays, skills, experience, techniques, results
of experimentation and testing, including clinical test data, analytical and
quality control data, regulatory submissions, copyrights, and other intellectual
property of any kind, not covered by claims of any Patent Rights, in each case
owned or Controlled by either Party or its Affiliates.

 

1.26                        “Licensed Healthcare Practitioner” shall
mean any Healthcare Practitioner who is licensed or authorized under the laws
and regulations of a country (or other applicable jurisdiction) to order
Prescription Products or Medical Diagnosis Products for humans.

 

1.27                        “Medical Diagnosis Product” shall mean any
diagnostic product or procedure that is intended for use in making a specific
medical diagnosis for human subjects, which use is lawful under applicable laws
or regulations or eligible for reimbursement by a governmental body or health
care payor in each case only if such use is prescribed by a Licensed Healthcare
Practitioner (in his/her capacity as such).

 

1.28                        “Net Revenues” shall mean collectively: (a)
Net Sales; (b) all revenues received by Sciona and its Affiliates from Third
Parties [**] in connection with [**]; and (c) all other revenue and
consideration received by Sciona and its Affiliates from Third Parties
(including Permitted Sciona Partners) in respect of [**], including [**].  For the avoidance of doubt, revenues and
other consideration received by Sciona and its Affiliates hereunder shall
include consideration in any form, including any license or distribution
signing fee, any license or distribution maintenance fee, minimum royalty
payments, lump sum payments and earned royalties, and shall also include
research and development funding and any consideration received for an equity
interest in, or other investment in Sciona (or an Affiliate) to the extent such
research and development funding or consideration is given as part of the same
transaction or related series of transactions with, and exceeds that which
would have been received in the absence of, the grant of the sublicense or
other rights hereunder.

 

1.29                        “Net Sales”
shall mean the gross sales revenues invoiced by Sciona and its Affiliates on
the sale, transfer, disposition or other provision of HAP Marker Genetic Tests,
less the following customary deductions: (i) normal and customary trade, cash
and other discounts, allowances and credits; (ii) credits or allowances
actually granted for damaged goods, returns or rejections; (iii) sales or similar
taxes that are included in the billing amount; (iv) freight, postage, shipping,
customs duties and insurance charges that are included in the billing amount
and (v) actual bad debts.  The transfer
or sale of HAP
Marker Genetic Tests by Sciona to an Affiliate of Sciona shall not
be considered a sale, but in such case, Net Revenues shall be determined based

 

5

 

on the invoiced sales price by the Affiliate to its Third Party
customer, less the deductions allowed under this Section 1.28.

 

1.30                        “Patent Rights” shall mean patents, patent
applications or supplementary protection certificates (SPCs) that are
owned or Controlled by a Party or its Affiliates.

 

1.31                        “Party” means Genaissance or Sciona, as the
case may be, and “Parties” means
Genaissance and Sciona.

 

1.32                        “Permitted Sciona Partner” shall mean any
(a) Affiliate, (b) any Third Party that is granted a sublicense by Sciona as
permitted pursuant by Section 2.1(c) in its capacity as such sublicensee;
and (c) any other Third Party that is granted distribution rights (or other
rights to purchase for resale) with respect to HAP
Marker Genetic Tests in its capacity as such distributor; provided, that Sciona may not grant any
Third Party sublicense or distribution rights hereunder (other than with the
prior written consent of Genaissance) if Genaissance already has entered
into an agreement with such Third Party or its Affiliates, which agreement
includes a license to HAP Markers
for use in the discovery, development, manufacturing, marketing or selling of,
or other activities relating to, Dual-Purpose Products, Prescription Products
or Medical Diagnosis Products.

 

1.33                        “Permitted Third Party Agreement” shall
mean an agreement that (a) is entered into after the Effective Date by
Genaissance and a Third Party who is engaged in the business of discovering,
developing, manufacturing, marketing or selling of Prescription Products or
Medical Diagnosis Products and (b) grants the Third Party a license to use the HAP Database, the HAP Markers or the DecoGen Informatics System (the “Licensed
Technology”) in a field of use that includes the development, manufacturing,
marketing and selling of Consumer Products and one or more of Prescription
Products or Medical Diagnosis Products, provided,
however, that (i) Genaissance reasonably believes the Third Party
intends to use the Licensed Technology to discover, develop, manufacture,
market or sell a Prescription Product or a Medical Diagnosis Product, and (ii)
if the Third Party seeks to partner with Genaissance or an Affiliate of
Genaissance to develop, manufacture,
market or sell a Consumer Product, then Genaissance will not agree to be such a
partner unless the Third Party agrees that Genaissance may use Sciona as
Genaissance’s exclusive partner for Consumer Products (and, for the avoidance
of doubt, Sciona shall have the right to require Genaissance to so partner with
Sciona on an exclusive basis).  For the avoidance of doubt, any such
partnering arrangement will be subject to Sciona’s and Genaissance’s rights and
obligations under Section 2.4, Section 2.5 and Article 3 of this
Agreement.

 

1.34                        “Phenotype” shall mean (a) an individual’s
response to any substance or treatment, including Consumer Products and
Prescription Products, or (b) the presence of, or susceptibility for, any
disease or condition.

 

6

 

1.35                        “Prescription Product” shall mean any
therapeutic product or therapeutic treatment that generally requires a
prescription by a Licensed Healthcare Practitioner under applicable laws or
regulations or is eligible for reimbursement by a governmental body or a health
care provider only if prescribed by a Licensed Healthcare Practitioner.

 

1.36                        “Sciona” or “Sciona Ltd.” shall mean Sciona Ltd.

 

1.37                        “Sciona Genetic Test” shall mean any
genetic test other than a HAP
Marker Genetic Test that (a) is developed, marketed or sold solely by Sciona or
one of its Affiliates or jointly by Sciona or one of its Affiliates and one or
more other parties, which may include Genaissance, and (b) is designed to
detect the presence or absence of a polymorphism or haplotype in a human
individual.

 

1.38                        “Third Party” shall mean any corporation,
person or other entity other than Genaissance or Sciona or their respective
Affiliates.

 

1.39                        “Transition Period” shall mean the period
of time commencing on the Effective Date and expiring on the first to occur of
the following: (a) [**] months thereafter, (b) on the date on which Sciona
first achieves positive net income determined in accordance with generally
accepted accounting principles in the United Kingdom consistently applied, or
(c) on the date on which Sciona and its Affiliates has first obtained or
achieved cumulative combined Third Party financing (equity or debt) and sales
revenues of at least $[**], as calculated on a monthly basis from the Effective
Date.  For
the avoidance of doubt, the amount of financing or sales revenues
obtained by Sciona before the Effective Date shall not be applicable to subpart
(c) of the preceding sentence.

 

1.40                        “Valid Claim” means any claim of an issued
and unexpired patent comprising a Patent Right, which claim has not been held
unenforceable, unpatentable or invalid by a final decision of a court or governmental agency of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal,
and which has not been admitted to be invalid or unenforceable through reissue,
re-examination or disclaimer and which is not subject to an interference action.  “Valid Claim”
also means any pending
application for a patent included within the Patent Rights to the extent the
invention(s) described in the claims of such application have not been
abandoned without being refiled in another application or finally rejected by
an administrative agency action from which no appeal can be taken.

 

1.41                        The following terms have the
meanings set forth in the corresponding Sections of this Agreement:

 

7

 

	
  Term

  	
   

  	
  Section

  
	
  “Access
  Period”

  	
   

  	
  10.1(a)

  
	
  “Genaissance Collaboration IP”

  	
   

  	
  3.3

  
	
  “HAP Marker Association
  Collaboration Agreement”

  	
   

  	
  3.2

  
	
  “Installation Site”

  	
   

  	
  2.8(a)

  
	
  “Investment Agreement”

  	
   

  	
  5.1

  
	
  “Joint Collaboration IP”

  	
   

  	
  3.3

  
	
  “Minimum Annual Payments”

  	
   

  	
  5.4

  
	
  “Royalties”

  	
   

  	
  5.2

  
	
  “Sciona Collaboration IP”

  	
   

  	
  3.3

  
	
  “Service Fees”

  	
   

  	
  5.3

  
	
  “Shares”

  	
   

  	
  5.1

  
	
  “Software Product”

  	
   

  	
  2.8(c)

  
	
  “Sublease”

  	
   

  	
  4.1

  

 

1.42                        Interpretation.  Whenever any provision of this Agreement
uses the term “including” (or “includes”), such term shall be deemed to mean
“including without limitation” and “including but not limited to” (or “includes
without limitations” and “includes but is not limited to”) regardless of
whether the words “without limitation” or “but not limited to” actually follow
the term “including” (or “includes”); “herein,” “hereby,” “hereunder,” “hereof”
and other equivalent words shall refer to this Agreement as an entirety and not
solely to the particular portion of this Agreement in which any such word is
used; all definitions set forth herein shall be deemed applicable whether the
words defined are used herein in the singular or the plural; wherever used
herein, any pronoun or pronouns shall be deemed to include both the singular
and plural and to cover all genders; all references to days, months, quarters
or years are references to calendar days, calendar months, calendar quarters or
calendar years; and any reference to any federal, national, state, local or
foreign statute or law shall be deemed to also refer to all rules and
regulations promulgated thereunder, unless the context requires otherwise.

 

8

 

2.                                      GRANT
OF RIGHTS

 

2.1                               HAP Technology License in the Field of Use.

 

(a)                                  During
the Access Period.  Subject to the
terms and conditions of this Agreement, Genaissance hereby grants to Sciona the
exclusive, worldwide license (with the limited rights to sublicense as set
forth in Section 2.1(c)) under Genaissance Know-How and Genaissance Patent
Rights to use the HAP Database,
the HAP Markers and the DecoGen Informatics System solely in the
Field of Use during the Access Period. 
Without limiting the rights and remedies contained in
Section 10.4(b) or otherwise available, if at any time Sciona breaches a
provision of Section 5.4 and Sciona fails to cure such breach within [**]
days after receipt of written notice from Genaissance (which notice shall be
served by Genaissance within [**] days following Genaissance’s actual knowledge
of such breach), Genaissance may, at its sole option, convert the exclusive
license described in clause 2.1(a)(i) to a non-exclusive license upon written
notice to Sciona; unless Sciona’s breach is solely due to Genaissance’s failure
to perform, in all material respects, its obligations under this Agreement or
any agreement entered into by the Parties with respect to Genetic Tests as
described in Sections 2.4 and 2.5.

 

(b)                                 Following
the Access Period.  Subject to the
terms and conditions of this Agreement, Genaissance hereby grants to Sciona the
exclusive, worldwide license (with the limited rights to sublicense as set forth in
Section 2.1(c)) under Genaissance Know-How and Genaissance Patent
Rights to use HAP Markers solely
in the further development, manufacturing, marketing and selling of HAP Marker Genetic Tests solely for use by
Sciona, Affiliates of Sciona, and other Permitted Sciona Partners in the
development, manufacturing, marketing and selling of (i) Consumer Products and
(ii) Dual-Purpose Products to the extent that such products are (or, in the
case of products in development or manufacture, are intended to be) marketed
and sold by Sciona and Permitted Sciona Partners solely as Consumer Products; provided, that, in each case, such HAP Markers
may only be used in HAP Marker
Genetic Tests developed solely by Sciona (or one of its Affiliates) or jointly
by the Parties during the Access Period pursuant to Article 3 herein.

 

(c)                                  Sublicense
Rights.  Sciona shall have the right
to grant sublicenses of the rights granted pursuant to this Section 2.1
and Section 3.3 to its Affiliates. 
In addition, to the extent required for the development, manufacture,
marketing, selling or performance of HAP
Marker Genetic Tests as permitted under the license rights granted to Sciona
pursuant to this Section 2.1 and Section 3.3, and consistent with the
rights granted to Genaissance pursuant to Section 2.4, Sciona shall have
the right to grant Third Parties the right to use the HAP Markers to be detected
by such HAP Marker Genetic
Tests.  Except to the extent provided in
the prior sentences, with respect to use of certain HAP Markers, Sciona’s right
to sublicense use of the HAP
Database shall be limited to only such portions of the HAP Database as may be necessary to market
and sell  HAP Marker Genetic Tests, Consumer
Products and Dual Purpose Products as may be agreed to by the Parties from time
to time, which agreement by Genaissance may not be unreasonably delayed or
withheld.

 

9

 

2.2                               HAP Technology Rights
Outside the Field of Use.  Subject
to any pre-existing Third Party rights, Genaissance hereby grants to Sciona a
non-exclusive option during the Access Period to obtain the non-exclusive
license under the Genaissance Patent Rights and Genaissance Know-How to use the
HAP Database, HAP Markers and the DecoGen Informatics System outside of the
Field of Use on such terms and conditions as the Parties may negotiate in good
faith.  For the avoidance of doubt, such
option shall not be applicable with respect to any pre-existing exclusive Third
Party rights or any exclusive rights granted by Genaissance to Third Parties at
any time during the Access Period.

 

2.3                               Reservation of Rights.  Notwithstanding the rights granted to Sciona under
this Article 2, Genaissance at all times reserves (a) its rights to the HAP Markers and other information
contained in the HAP Database,
(b) its right to use the HAP Database
and DecoGen Informatics System to
research, develop, have developed, use, manufacture, have manufactured, sell
and have sold products, including the right to grant exclusive and
non-exclusive licenses to Third Parties with respect to Genaissance Know-How or
Patent Rights related to such purposes outside the Field of Use, and (c) its
right to perform genotyping services for Third Parties engaged in the business
of discovering, developing, manufacturing, marketing or selling of Consumer
Products even if the polymorphisms to be genotyped pursuant to such services
are in the HAP Database, provided, however, that such polymorphisms
are specified solely by the Third Party without access to or use of the HAP Database.

 

2.4                               HAP Marker Genetic Tests.  Sciona hereby grants to Genaissance the
exclusive right during the Access Period (a) to develop genotyping assays for
the HAP Marker Genetic Tests, and
(b) subject to any pre-existing Sciona arrangement described on Schedule 2.4,
to process or perform HAP Marker
Genetic Tests sold by Sciona and Permitted Sciona Partners to customers in a
Genaissance Territory and returned by the consumer (or relevant Third Party)
for analysis.  The specific assay
quality and other performance requirements for such services shall be agreed to
by the Parties on a project-by-project basis. 
Sciona shall pay Genaissance fees for  such
assay development services and for such performance of HAP Marker Genetic Tests, which fees shall
be determined in accordance with Section 5.3.  If Genaissance fails to perform satisfactorily, in all material
respects, the services described in this Section 2.4 with respect to a
specific HAP Marker Genetic Test,
then Sciona (or any applicable Permitted Sciona Partner) shall be able to enter
into an agreement with a Third Party for the provision of such services with
respect to such HAP Marker
Genetic Test.

 

2.5                               Sciona Genetic Tests.

 

(a)                                  Rights
of First Negotiation.  As provided
in Section 2.5(b) below, Sciona shall grant to Genaissance and its
Affiliates rights of first negotiation during the Access Period: (i) to develop
genotyping assays for any and all Sciona Genetic Tests, and (ii) subject to any
pre-existing Sciona arrangement described on Schedule 2.4 (as amended
from time to time),  to perform
any and all Sciona Genetic Tests sold in a Genaissance Territory.  Sciona shall pay

 

10

 

Genaissance fees for such assay development services and for such
performance of the Sciona Genetic Tests, which fees shall be determined in
accordance with Section 5.3.

 

(b)                                 Notice.  If, at any time during the Access Period,
Sciona wishes to develop a new Sciona Genetic Test or materially change an
existing Sciona Genetic Test, or Sciona wishes to sell Sciona Genetic Tests in
a Genaissance Territory, then save to the extent that the development, change
or sale of such Sciona Genetic Test is subject to any pre-existing Sciona
arrangement described on Schedule 2.4 (as amended from time to time),
Sciona shall promptly notify Genaissance and grant Genaissance the exclusive
right to negotiate, in accordance with Section 2.5(c), the right to
develop genotyping assays for such Genetic Test, or perform such Genetic Test
in the Genaissance Territory, as the case may be.

 

(c)                                  Negotiating
Period. If Genaissance notifies Sciona within [**] days after receipt of
the notice described in Section 2.5(b) that Genaissance desires to
negotiate an arrangement regarding the relevant Sciona Genetic Test, then for
[**] days following Genaissance’s notice, Sciona will negotiate [**] with
Genaissance on a good faith basis to reach a definitive agreement with
Genaissance with respect to the Sciona Genetic Test.  If Genaissance fails to provide written notice to Sciona as
specified in this Section 2.5(c) or the Parties fail to reach agreement on
the principal terms of such arrangement (including compensation) within [**]  days after
Genaissance provides Sciona with written notice, Sciona will be permitted to
enter into negotiations and conclude an agreement with a Third Party, subject
to Genaissance having a [**] day right of refusal to substantially match any
agreement reached by Sciona and a Third Party.

 

2.6                               No Grant of Other Technology or Patent Rights and
Covenant Not to Sue.

 

(a)                                  Except
as otherwise expressly provided in this Agreement, under no circumstances shall
a Party hereto or its Affiliates, as a result of this Agreement, obtain any
ownership interest in or other right to any technology, know-how, patents,
patent applications, data, products, or biological materials of the other Party
or its Affiliates, including items owned, Controlled or developed by the other
Party or its Affiliates, or transferred by the other Party or its Affiliates to
said Party, at any time pursuant to this Agreement.

 

(b)                                 Genaissance
covenants and agrees (on its behalf and on behalf of its Affiliates) that, for
so long as Sciona is compliant with its royalty obligations pursuant to
Section 5.2, it shall not assert against Sciona or any Permitted Sciona
Partner any patent or other intellectual property right that would block Sciona
or Permitted Sciona Partners from exercising the license rights granted
pursuant to Sections 2.1 and 3.3.

 

2.7                               Third Party Patents. 
The Parties acknowledge that, in order to discover, develop
and/or commercialize one or more products, they may require licenses under
Third Party patent rights or other rights, and it is hereby agreed that it
shall be each Party’s responsibility to satisfy itself as to the need for such
licenses and, if necessary, to obtain such licenses at its sole cost and
expense.

 

11

 

2.8                               Installation and Use of the HAP Technology.

 

(a)                                  Installation,
Training, Support and Updates. 
Genaissance shall install, [**] the DecoGen
Informatics System and the HAP
Database on a Sciona database server at Sciona’s [**] facility located at [**]
(the “Installation Site”) at a time mutually agreed upon by the Parties.  Genaissance will provide, [**] of on-site
training at the Installation Site, installation documentation, and a user
manual.  For the duration of the Access
Period, phone or email support will also be available to Sciona between the
hours of 8:30 A.M. and 5:30 P.M. (Eastern Standard Time) Mondays through
Fridays, except when Genaissance is officially closed (e.g., for holidays or
weather emergencies).  Genaissance shall
provide any updates to the DecoGen
Informatics System and the HAP
Database at the Installation Site on a [**] basis.

 

(b)                                 Remote
Access.  Sciona may access the DecoGen Informatics System and the HAP Database at the Installation Site from
computers at other remote Sciona sites and Sciona shall have the right to
install copies of the DecoGen
Informatics System and the HAP
Database at different Sciona sites (or have all copies transferred to another
Sciona site).  Should Sciona request the
assistance of Genaissance in accessing or transferring the DecoGen Informatics System and the HAP Database, Sciona shall reimburse
Genaissance for [**] in providing such assistance.

 

(c)                                  Restrictions
on Use.  Sciona’s use of the DecoGen Informatics System and the HAP Database (each, a “Software Product”)
shall be subject to the following conditions:

 

(i)                                     To the extent that
a Software Product incorporates or requires the use of any commercially
available operating system software that is licensed by Genaissance from a
Third Party as described in Exhibit 1.7, as may be supplemented from
time to time, and Genaissance does not have the right to freely sublicense such
Third Party software, Sciona shall be responsible for obtaining any necessary
license and paying all fees and charges associated with Sciona’s use of any
such software;

 

(ii)                                  Sciona agrees to use
the Software Products in accordance with the terms and conditions of this
Agreement and not to use the Software Products for processing data for Third
Parties other than Permitted Sciona Partners, or to make the Software
Product(s) available to Third Parties except as permitted pursuant to
Section 2.1(c);

 

(iii)                               Sciona agrees to make
copies of the Software Products (or any part of the contents thereof) only to
the extent reasonably necessary for the exercise of its rights hereunder, and
that all such copies will be treated as Confidential Information of Genaissance
and further agrees to establish reasonable security measures to prevent copies
of the Software Products from being made available to unauthorized Third
Parties;

 

12

 

(iv)                              Except with the express
written permission of Genaissance, Sciona agrees that it will not attempt to
reverse engineer, reverse compile or otherwise obtain access to the source code
of the Software Products; and

 

(v)                                 Sciona may not adapt
or modify the Software Products without the express written permission of
Genaissance.

 

3.                                      HAP MARKER ASSOCIATION DISCOVERY SERVICES.

 

3.1                               Collaboration.  During the Access Period, (a) Sciona and
its Affiliates shall collaborate with Genaissance and its Affiliates on an exclusive
basis to discover HAP Marker
Associations in the Field of Use (including Dual-Purpose Products) or to sell
(or provide to Third Parties) HAP
Marker Association discovery services in the Field of Use; and (b) Genaissance
and its Affiliates shall collaborate with Sciona and its Affiliates on an
exclusive basis to discover HAP
Marker Associations in the Field of Use or to sell (or provide to Third
Parties) HAP Marker Association
discovery services in the Field of Use; provided,
that if Sciona’s exclusive license described in clause 2.1(a)(i) is converted
to a non-exclusive license pursuant to Section 2.1(a), the obligation of
Genaissance and its Affiliates to collaborate on an exclusive basis shall be
converted to a non-exclusive obligation.

 

3.2                               HAP Marker Association
Collaboration Agreement.  The
further terms that the Parties may agree to from time to time in relation to
any collaboration to discover HAP Marker
Associations will be the subject of a separate agreement to be negotiated in
good faith by the Parties (a “HAP Marker
Association Collaboration Agreement”).  The fee paid by Sciona for any particular service performed
pursuant to a HAP Marker Association Collaboration Agreement shall [**].

 

3.3                               Intellectual Property Rights.  Save as otherwise expressly
agreed in the HAP Marker
Association Collaboration Agreement, (i) Genaissance shall own all HAP Marker Association Patent Rights and
related Know-How conceived or reduced to practice by either Party or its
Affiliates in the conduct of such collaboration and all other intellectual
property conceived or reduced to practice solely by employees, agents and
consultants of Genaissance or its Affiliates in the conduct of such
collaboration (collectively the “Genaissance
Collaboration IP”), subject to the exclusive right to Sciona to
exploit the Genaissance Collaboration IP in the Field of Use as provided in
Section 2.1; (ii) Sciona shall own all other intellectual property
conceived or reduced to practice solely by employees, agents or consultants of
Sciona or its Affiliates in the conduct of such collaboration (the “Sciona Collaboration IP”), subject to a
non-exclusive right to Genaissance and its Affiliates to exploit the Sciona
Collaboration IP outside of the Field of Use; and (iii) all other intellectual
property conceived or reduced to practice jointly by employees, agents or
consultants of Sciona or its Affiliates and employees, agents and consultants
of Genaissance or its Affiliates in the conduct of such collaboration (the “Joint Collaboration IP”) shall be owned
jointly by Genaissance and Sciona; provided,
that Sciona shall have the exclusive right to exploit all such Joint
Collaboration IP in the Field of Use as

 

13

 

provided in Section 2.1 and both Parties shall have the
non-exclusive right to exploit all such Joint Collaboration IP outside of the
Field of Use.  With respect to the Joint
Collaboration IP, subject to each Party’s license rights, each of the Parties
shall be free to use and exploit the Joint Collaboration IP without any
accounting or payment to, or consent of, the other Party; provided, that either Party may only sell, license, sub-license or
otherwise transfer its rights in any such invention without the consent of the
other Party in a manner that is consistent with the licenses granted pursuant
to this Agreement and is otherwise consistent with this Agreement.

 

4.                                      PRODUCT
AND BUSINESS DEVELOPMENT

 

4.1                               United
States Operations.  Unless otherwise
agreed to by the Parties, during the Access Period and subject to the consent
of Genaissance’s landlord, Genaissance shall grant Sciona and its Affiliates
the right to occupy and conduct their business from premises located at Five
Science Park, New Haven, Connecticut as provided in a sublease agreement, by
and between the Parties (the “Sublease”),
substantially in the form as Exhibit 4.1 hereto.  The Sublease shall provide, among other
things, that (a) Genaissance [**] Sciona [**] during the Transition Period, and
(b) following the Transition Period, for the remainder of the Access Period (or
if shorter, such period as Sciona is in actual occupation of such space
pursuant to the Sublease), Sciona [**] Genaissance [**]  Unless otherwise agreed by the Parties, the
Sublease shall [**].

 

4.2                               Business Development Support.  During the Transition Period,
Genaissance shall provide Sciona or its United States’ Affiliate with the
following business development and technical support services: (a) one full
time project manager (the identity of which manager shall be reasonably
acceptable to Sciona and Genaissance and who shall be an employee of
Genaissance); (b) [**] percent ([**]%) of the costs of a senior business
development manager (which manager shall initially be Melisse Shaban and
thereafter, such person shall be reasonably acceptable to Sciona and
Genaissance and who shall be a consultant hired for such purpose or otherwise
an employee of Genaissance), (c) access to senior Genaissance scientists,
including the [**] to support Sciona’s business development activities as
reasonably required by Sciona but not to exceed [**] percent ([**]%) of a
full-time equivalent unless otherwise agreed to by Genaissance, (d) [**]
percent ([**]%) of the Third Party search fee to identify and recruit a Chief
Executive Officer for Sciona, and (e) use of other facilities and members of
Genaissance’s [**] teams from time-to-time as reasonably required by Sciona to
carry out the operations contemplated by this Agreement.  Such
services shall be subject to such reasonable limitations as the Parties shall
negotiate in good faith upon the reasonable request of Genaissance.

 

5.                                      FINANCIAL
TERMS

 

5.1                               Shares
of Sciona Stock.  As consideration
for the rights granted to Sciona pursuant to Article 2, Genaissance will
acquire 152,290 shares of Sciona stock (the “Shares”) pursuant to the terms of an
Investment Agreement, dated as of the Effective Date, by and between the
Parties in substantially the form of Exhibit 5.1 hereto (the “Investment Agreement”).

 

14

 

The number of Shares issued to Genaissance is, as of the Effective
Date, equal to thirty percent (30%) of the issued share capital of Sciona on a
fully diluted basis taking into account: (i) all unissued shares in the capital
of Sciona allocated to the employee option pool of Sciona (whether or not
options have been granted over such shares and in any event being not less than
50,408 Ordinary Shares, (ii) 44,444 A Ordinary Shares which may be issued in
connection with [**] (whether or not such deferred consideration shares are
actually issued), and (iii) the Shares acquired by Genaissance pursuant to the
Investment Agreement.

 

5.2                               Royalties.  Sciona will pay Genaissance, on a quarterly basis, a royalty equal
to [**] percent ([**]%) of Net Revenues, less any Service Fees paid to
Genaissance by Sciona for the performance of HAP
Marker Genetic Tests in the Genaissance Territory during such
quarter (the “Royalty”).  The Royalties shall be payable on a
country-by-county and Test-by-Test basis for the longer of (a) ten (10) years
after the date of First Commercial Sale of such Genetic Test, or (b) the last
to expire of Genaissance’s Patent Rights covering any applicable HAP Marker(s) or HAP Marker Association.  The Royalties shall be due within [**] days
following the end of each quarter.  The Parties
acknowledge that Royalties may be payable after the expiration of the life of
all Valid Claims covering the applicable HAP
Marker(s) or HAP Marker
Association; however, the Parties have agreed that such Royalties are payable
on the sale of products that were developed only during the life of such Claims
and that no Royalty is payable on any products developed by the practice of
such Claims after their expiration.  Because
of the nature of the Valid Claims, the Parties believe that their economic
value can be measured only by reference to the sales of products developed by
the practice of such Valid Claims and such method is fair and equitable, even
though the sales may occur following expiration of the Valid Claims.

 

5.3                               Service Fees.  In consideration for the development of genotyping assays for the
Genetic Tests and the performance of such Genetic Tests in a Genaissance
Territory (as described in Sections 2.4 and 2.5 above), Sciona will pay Genaissance
fees to be agreed to by the Parties on a project-by-project basis, which fees
shall [**], plus [**] percent ([**]%) (the “Service
Fees”).

 

5.4                               Minimum Payments.  Sciona shall pay Genaissance the following aggregate minimum
levels of Royalties and Service Fees (the “Minimum
Annual Payment”) each
year during the Access Period:

 

	
  Calendar Year

  	
   

  	
  Minimum Annual Payment

  
	
   

  	
   

  	
   

  
	
  2003

  	
   

  	
  $

  	
  [**]

  
	
  2004

  	
   

  	
  $

  	
  [**]

  
	
  2005

  	
   

  	
  $

  	
  [**]

  
	
  2006

  	
   

  	
  $

  	
  [**]

  
	
  2007

  	
   

  	
  $

  	
  [**]

  

 

[**] shall be payable after the Access Period.  For 2003, the aggregate Royalties and
Service Fees paid by Sciona to Genaissance shall be calculated within [**] days
following [**]; thereafter, the

 

15

 

aggregate Royalties and Service Fees paid by Sciona to Genaissance
shall be calculated every [**] (i.e., within [**] days following [**]).  In the event that the aggregate Royalties
and Services Fees are less than the Minimum Annual Payment (or [**] percent
([**]%) of the Minimum Annual Payment for calculations made [**]), Sciona will
pay Genaissance the Minimum Annual Payment (or [**] percent ([**]%) thereof as
applicable) less the aggregate Royalties and Service Fees paid by Sciona.  Such payment shall be made within [**] days
following [**], as applicable.

 

5.5                               Royalty Reports and Audits.

 

(a)                                  Royalty
Reports.  Within [**] days following
each quarter, Sciona shall furnish to Genaissance a written quarterly report
showing: (i) the gross sales of HAP Marker Genetic Tests during the
reporting period and the calculation of Net Revenues from such gross sales
(including the deductions allowed under Section 1.28); (ii) all other
consideration received by Sciona and its Affiliates in connection with this
Agreement; (iii) the Service Fees paid to Genaissance during the reporting period;
(iv) the calculations of Net Sales, Net Revenues and Royalties for such
reporting period; (v) withholding taxes, if any, required by law to be deducted
in respect of such Royalties; (vi) the dates of the First Commercial Sales of HAP Marker Genetic Tests in any country
during the reporting period; and (vii) the exchange rates used in determining
the amount of United States dollars payable hereunder.  If no Royalty is due for any royalty period
hereunder, Sciona shall so report. 
Sciona and its Affiliates shall keep complete and accurate records in
sufficient detail to properly reflect Net Revenues and to enable the Royalties
payable hereunder to be determined.

 

(b)                                 Audits.  Upon the written request of Genaissance,
Sciona shall permit an independent certified public accountant selected by
Genaissance and acceptable to Sciona, which acceptance shall not be
unreasonably withheld, to have access during normal business hours to such
records of Sciona and its Affiliates as may be necessary to verify the accuracy
of the Royalties described herein.  Both
Parties shall use commercially reasonable efforts to schedule all such
verifications within [**] days after Genaissance makes its written request.  In the event Genaissance’s independent
certified public accountant concludes that additional Royalties were owed to
Genaissance during such period, the additional Royalty shall be paid by Sciona
within [**] days of the date Genaissance delivers to Sciona such independent
certified public accountant’s written report so concluding, with interest
thereon accruing under this Agreement. 
In the event Genaissance’s independent certified public accountant
concludes that there was an overpayment of Royalties to Genaissance during such
period, the overpayment shall be repaid by Genaissance within [**] days of the
date Genaissance received such independent certified public accountant’s
written report so concluding.  The fees
charged by such independent certified public accountant shall be paid by Genaissance
unless the audit discloses an underpayment of the Royalties payable by Sciona
for the audited period of more than [**] percent ([**]%), in which case Sciona
shall pay the reasonable fees and expenses charged by such representative.

 

5.6                               Withholding Taxes.  Sciona shall deduct withholding taxes from
Royalties and pay them to the proper tax authorities only to the extent
required by applicable laws.  Sciona
shall

 

16

 

be responsible for all other taxes, duties and other governmental
charges, including value added taxes (VAT) and import duties, and shall not
deduct any other withholding or any other taxes, duties or governmental charges
from the payments under this Agreement, save to the extent required by
applicable laws.  Sciona shall maintain
official receipts of payment of any withholding taxes and forward these
receipts to Genaissance within [**] days. 
The Parties will exercise diligent efforts to ensure that any
withholding taxes imposed are reduced as far as possible under the provision of
any treaties applicable to any payment made hereunder.

 

5.7                               Late Payments.  Any payments that have not been paid thirty (30) days after the
date such payments are due under this Agreement shall entitle, but not
obligate, Genaissance to charge interest on the outstanding payment at a rate
equal to the prime rate as published in The Wall Street Journal, Eastern
Edition, on the first day of each calendar quarter in which such payments are
overdue, plus two (2) percentage points, calculated on the number of days such
payment is delinquent.

 

5.8                               Currency Exchange; Blocked Currency.  All payments shall be made in United States
dollars in immediately available funds. 
With respect to Net Revenues invoiced or received (as the case may be)
in a currency other than United States dollars, the Royalties shall be
expressed in the foreign currency of the entity making and then converted to
United States dollars by using the selling exchange rate for conversion of the
foreign currency into United States Dollars, quoted for current transactions
reported under the heading “Currency Trading – Exchange Rates” in The Wall
Street Journal in the United States for the last business day of
such reporting period to which such payment pertains.  If The Wall Street Journal ceases to be published, then the
rate of exchange to be used shall be that reported in such other business
publication of national circulation in the United States as the Parties
reasonably agree.  If at any time legal
restrictions in any country prevent the prompt remittance of any payments with
respect to sales or services in that country, Sciona shall have the right and
option to make such payments by depositing the amount thereof in local currency
to Genaissance’s account in a bank or depository in such country.

 

6.                                      INTELLECTUAL PROPERTY

 

6.1                               Ownership
of Intellectual Property.

 

(a)                                  Ownership
of the HAP Marker  Database and DecoGen Informatics System.  Subject to the rights and licenses granted under this Agreement, and subject to any
pre-existing rights of Third Parties, Genaissance shall have sole
ownership of (i) the HAP Database
and all information contained therein, and (ii) the DecoGen Informatics System.

 

(b)                                 Ownership
of HAP Markers.  Genaissance shall have sole ownership of all
right, title and interest in all HAP
Markers, and, subject to Section 6.2(c) all HAP Marker Patent Rights. 
Sciona and its Affiliates shall execute and deliver, without charge to
Genaissance (other than reimbursement of Sciona’s reasonable out of pocket
costs and expenses), assignment of all

 

17

 

of its right, title and interest in and to HAP Markers to Genaissance subject to Sciona’s right to use
the HAP Markers pursuant to the
terms of this Agreement.

 

(c)                                  Ownership
of HAP Marker Associations.  Genaissance shall have sole ownership of all
right, title and interest in all HAP
Marker Associations and, subject to Section 6.2(c), all HAP Marker Association Patent Rights,
including without limitation Genaissance Collaboration IP.  Sciona and its Affiliates shall disclose to
Genaissance any HAP Marker
Associations discovered solely by employees of Sciona or its Affiliates or
others acting on their behalf.  All
information relating to such HAP Marker Associations shall be deemed the Confidential Information
of Genaissance subject to the terms of Article 7, and Genaissance shall take all reasonable
steps to maintain such information in confidence consistent with those steps
taken to protect other information that Genaissance regards as proprietary or
confidential and that is of similar value or importance.  Sciona
shall execute and deliver, without charge to Genaissance (other than
reimbursement of Sciona’s reasonable out of pocket costs and expenses),
assignment of all of its right, title and interest in and to HAP Marker Associations to Genaissance
subject to Sciona’s right to use the HAP
Marker Associations pursuant to the terms of this Agreement.

 

(d)                                 Cooperation
of Employees.  Each Party represents
and agrees that all employees or others acting on its behalf or on behalf of
its Affiliates pursuant to this Agreement shall be obligated under a binding
written agreement to assign to such Party all inventions made or conceived by
such employee or other person.

 

6.2                               Filing, Prosecution and Maintenance of Patent Rights.

 

(a)                                  Filing, Prosecution and Maintenance. 
Subject to Section 6.2(c) below, Genaissance shall have sole
responsibility for and control over the filing, prosecution and maintenance of
the Genaissance Patent Rights, [**].

 

(b)                                 Cooperation.  Genaissance shall keep Sciona informed
regarding the status and prosecution of the HAP
Marker Patent Rights and the HAP
Marker Association Patent Rights licensed to Sciona.  Sciona shall be provided [**] with copies of all correspondence
with the U.S. Patent & Trademark Office (or the applicable foreign patent
office) and with the opportunity to review and comment upon any papers,
responses or other filings prepared by Genaissance for submission to the said
offices [**] of their filing and Genaissance shall use reasonable efforts to
incorporate any comments requested by Sciona.

 

(c)                                  Assignment.  In the event that (i) Genaissance determines
that it will not seek Patent Rights with respect to any potentially patentable HAP Marker or HAP Marker Association licensed to Sciona pursuant to
Section 2.1(a), or (ii) Genaissance files patents claiming HAP Markers
or HAP Marker
Associations in one or more countries but subsequently determines, on a
country-by-country basis, that it will not file, prosecute or maintain any
Genaissance Patent Right for which Sciona has license rights, then Genaissance
shall promptly notify Sciona and any other licensee of such Genaissance Patent
Rights of its decision.  Sciona and any
other licensee of such

 

18

 

Genaissance Patent Rights shall, without charge to Sciona (other than
reimbursement of Genaissance’s reasonable out of pocket costs and expenses)
have the option to require Genaissance to assign absolutely all right, title
and interest in such Genaissance Patent Rights to Sciona and any such other
licensee.

 

6.3                               Enforcement of the Patent Rights.

 

(a)                                  Right to Enforce by Genaissance.  Each
Party agrees to provide written notice to the other Party promptly after
becoming aware of any infringement of any of the Genaissance Patent Rights
licensed to Sciona.  The Parties shall
discuss a strategy to prosecute any such infringement.  If the Parties do not agree on whether or
how to proceed with enforcement activity (i) within [**] days following the
notice of alleged infringement, or (ii) within [**] days before the time limit,
if any, set forth in the appropriate laws and regulations for filing of such
actions, whichever comes first, then Genaissance shall have the right, but not
the obligation, to take any action that it reasonably deems necessary to obtain
a discontinuance of such infringement or to bring suit against the Third Party
infringer.  Sciona and its Affiliates
will reasonably cooperate with Genaissance in any such suit or action and
Genaissance shall reimburse Sciona and its Affiliates for their reasonable out
of pocket expenses as provided in Section 6.3(c) below.  Genaissance shall keep Sciona reasonably
informed of all material developments in connection with any such claim, suit
or proceeding.

 

(b)                                 Right
to Enforce by Sciona.  In the event Genaissance does not take
any action to obtain a discontinuance of such infringement or bring suit
against the Third Party infringer within [**], then Sciona shall have the
right, but not the obligation, at its own expense to bring suit against the
Third Party infringer.  If required by
law, Genaissance shall permit any action under this Section 6.3 to be
brought in its name, including being joined as party-plaintiffs.  Sciona acknowledges that other Third Parties
may be licensees of the Genaissance Patent Rights and shall have rights
identical to Sciona to prosecute infringers. 
In any suit or action by Sciona in which Genaissance, as necessary, is named
a party-plaintiff as owner of the Genaissance Patent Rights, Genaissance shall
notify such other licensees, if any, of the existence of such legal action and
allow the other licensees to join as a plaintiff upon such licensees’
request.  In addition, in the event
another licensee instigates an infringement suit or action, Sciona and its
Affiliates hereby consent to being joined as plaintiffs in such suit solely for
the purpose of procuring standing to bring the action and at the sole expense
of the instigating licensee.  To the
extent Sciona desires to participate in any strategic decisions affecting the
prosecution of the action brought by another licensee, Sciona acknowledges that
it and the other licensee(s) will necessarily have to reach a mutual agreement
concerning strategy, litigation expenses and subject to Section 6.3(c)
below, sharing of any recovery or damages. 
In no event shall Sciona or any other licensee enter into any settlement
which admits or concedes that any aspect of the Genaissance Patent Rights is
invalid or unenforceable without the prior written consent of Genaissance,
which consent shall not be unreasonably withheld or delayed.  Genaissance will reasonably cooperate with
Sciona and any other licensee in any suit or action and Sciona shall reimburse
Genaissance and its Affiliates for their reasonable out of pocket expenses as
provided in Section 6.3(c) below. 
In no event shall

 

19

 

Genaissance incur any liability or expense in connection with any
action of Sciona or its Affiliates or any joint action of Sciona or its
Affiliates and any other licensee.

 

(c)                                  Procedures;
Expenses and Recoveries.  Subject to
any Third Party licensee’s rights as described in Section 6.3(b), the
Party initiating any infringement suit or action under this Section 6.3
shall have the sole and exclusive right to select counsel for any such suit or
action and shall pay all expenses of the suit, including attorneys’ fees and
court costs.  If such Party obtains any
damages, license fees, royalties or other compensation (including any amount
received in settlement of such litigation) in connection with such suit or
action, such amounts shall be allocated between the Parties as follows:

 

(i)                                     First, the Party
(and its Affiliates) initiating such suit or action shall be reimbursed for all
expenses of the suit or action, including attorneys’ fees and disbursements,
court costs and other litigation expenses not otherwise recovered;

 

(ii)                                  Second, the other
Party (and its Affiliates) shall be reimbursed for all expenses of the suit or
action, including attorneys’ fees and disbursements, court costs and other
litigation expenses not otherwise recovered; and

 

(iii)                               Third, the balance shall
be allocated between the Parties as follows: [**] percent ([**]%) to the Party
initiating the suit or action and [**] percent ([**]%) to the other Party.

 

6.4                               Patent Marking.  Sciona agrees to comply (and to cause its Affiliates
and other Permitted Sciona Partners to comply) with any applicable patent
marking statutes in any country in which HAP
Marker Genetic Tests are sold hereunder.

 

7.                                      CONFIDENTIALITY

 

7.1                               Confidential
Information.       All
Confidential Information disclosed by a Party or its Affiliates (the “Disclosing
Party”) to the other Party or its Affiliates (the “Receiving
Party”) during the term of this Agreement shall not be used by the
Receiving Party except in connection with the activities contemplated by this
Agreement or in order to further the purposes of this Agreement, shall be
maintained in confidence by the Receiving Party and shall not otherwise be
disclosed by the Receiving Party to any Third Party who is not a consultant of,
or an advisor to, or a Permitted Sciona Partner of, the Receiving Party,
without the prior written consent of the Disclosing Party, except to the extent
that the Confidential Information:  (a)
was known or used by the Receiving Party prior to its date of disclosure to the
Receiving Party, as demonstrated by legally admissible evidence available to
the Receiving Party; (b) either before or after the date of the disclosure to
the Receiving Party is lawfully disclosed to the Receiving Party by sources
other than the Disclosing Party rightfully in possession of the Confidential
Information and not bound by confidentiality obligations to the Disclosing
Party; (c) either before or after the date of the disclosure to the Receiving
Party becomes published or generally known to the public through no

 

20

 

fault or omission on the part of the Receiving Party; or (d) is
independently developed by or for the Receiving Party without reference to or
reliance upon the Confidential Information, as demonstrated by competent
written records.  In addition, the
provisions of this Section 7.1 shall not preclude the Receiving Party from
disclosing Confidential Information to the extent such Confidential Information
is required to be disclosed by the Receiving Party to comply with applicable
laws, to defend or prosecute litigation or to comply with governmental
regulations; provided that the
Receiving Party provides prior written notice of such disclosure to the
Disclosing Party, provides the Disclosing Party, to the extent possible, with
sufficient time and opportunity to obtain a protective order for such
Confidential Information and takes reasonable and lawful actions to avoid
and/or minimize the degree of such disclosure. 
Specific information shall not be deemed to be within any of the
foregoing exclusions merely because it is embraced by more general information
falling within these exclusions.

 

7.2                               Employee
and Advisor Obligations. 
Genaissance and Sciona each agree that they shall provide Confidential
Information received from the other Party or its Affiliates only to their
respective employees, consultants, advisors, Permitted Sciona Partners who have
a need to know such Confidential Information to assist such Party or its
Affiliates in fulfilling its obligations under this Agreement, provided that such Affiliates, employees,
consultants, advisors, and Permitted Sciona Partners agree to treat such
information and materials as confidential and to use such information and
materials in accordance with the terms of this Agreement.

 

7.3                               Injunctive Relief. 
The Parties hereto understand and agree that remedies at law
may be inadequate to protect against any breach of any of the provisions of
this Article 7 by either Party or their Affiliates, employees, agents,
officers or directors or any other person acting in concert with it or on its
behalf.  Accordingly, each Party and its
Affiliates may be entitled to the granting of injunctive relief by a court of
competent jurisdiction against any action that constitutes any such breach of
this Article 7.

 

7.4                               Publication.  Either
Party may publish or present data and/or results generated utilizing the HAP Markers, provided, that in the event that a Party or one of its
Affiliates desire to publish or present any Confidential Information of the
other Party or its Affiliates, then the proposed disclosure shall be subject to
the prior review by the other Party solely to determine (i) whether the
proposed disclosure contains the Confidential Information of the other Party or
its Affiliates or (ii) whether the information contained in the proposed
disclosure should be the subject of a patent application prior to such
disclosure.  Each Party shall provide
the other Party with the opportunity to review any proposed abstract,
manuscript or presentation which discloses Confidential Information of the
other Party or its Affiliates by delivering a copy thereof to the other Party
no less than [**] days before its intended submission for publication or
presentation.  The other Party shall
have [**] days from its receipt of any such abstract, manuscript or presentation
in which to notify the Party in writing of any specific objections to the
disclosure, based on either the need to seek patent protection or concern
regarding the specific disclosure of the Confidential Information.  In the event a Party objects to the
disclosure, the other Party agrees

 

21

 

not to submit the publication or make the presentation containing the
objected-to information until the Party is given a reasonable additional period
of time (not to exceed an additional [**] days) to seek patent protection for
any material in the disclosure which it believes is patentable or, in the case
of Confidential Information, to allow the Party to delete any Confidential
Information of the other Party or its Affiliates from the proposed disclosure.  Each Party agrees to delete from the
proposed disclosure any Confidential Information of the other Party or its
Affiliates upon request.

 

8.                                      REPRESENTATIONS AND WARRANTIES

 

8.1                               Representations,
Warranties and Covenants of Genaissance. 
Genaissance represents and warrants to and covenants with Sciona
that:

 

(a)                                  Genaissance
is a corporation duly organized, validly existing and in corporate good
standing under the laws of the State of Delaware;

 

(b)                                 Genaissance
has the legal right, authority and power to enter into this Agreement and to
grant the rights and licenses granted to Sciona in this Agreement, including
the license of Genaissance Patent Rights and Genaissance Know-How and the
rights to use the HAP Markers and DecoGen Informatics System, in
each case in accordance with the terms of this Agreement;

 

(c)                                  Genaissance
has taken all necessary action to authorize the execution, delivery and
performance of this Agreement;

 

(d)                                 upon
the execution and delivery of this Agreement, this Agreement shall constitute a
valid and binding obligation of Genaissance enforceable in accordance with its
terms, except as enforceability may be limited in the future by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors’ and contracting parties’ rights generally and except as
enforceability may be subject to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law);

 

(e)                                  the
performance of its obligations under this Agreement will not conflict with its
charter documents or result in a breach of any agreements, contracts or other
arrangements to which it is a party;

 

(f)                                    all
of its employees, officers, consultants and advisors who are supporting the
performance of its obligations under this Agreement shall have executed or will
have executed agreements or have existing obligations under law requiring
assignment to Genaissance of all intellectual property made during the course
of and as the result of their association with Genaissance and obligating the
individual to maintain as confidential Genaissance’s Confidential Information
as well as confidential information of a Third Party that Genaissance may
receive, to the extent required to support Genaissance’s obligations hereunder;

 

22

 

(g)                                 Except
as otherwise disclosed in writing to Sciona prior to the Effective Date,
Genaissance is not engaged in, has not received any written notice of, and is
not aware of any written threat of, litigation, arbitration or other judicial
proceeding alleging that the Genaissance Patent Rights, Genaissance Know-How
and/or DecoGen
Informatics System (or any part of any of the foregoing) infringes a
Third Party’s intellectual property rights;

 

(h)                                 Genaissance
is not aware of any existing, pending or threatened infringement of the
Genaissance Patent Rights, Genaissance Know-How or DecoGen Informatics System
by a Third Party;

 

(i)                                     to
the best of Genaissance’s actual knowledge, the existing rights of Genaissance
in the Genaissance Patent Rights, Genaissance Know-How and DecoGen Informatics System
as licensed to Sciona, its Affiliates and Permitted Sciona Partners pursuant to
this Agreement do not infringe any right, title or interest of any Third Party;

 

(j)                                     to
the best of Genaissance’s actual knowledge, the Genaissance Patent Rights,
Genaissance Know-How and DecoGen Informatics System are owned by
Genaissance free from all encumbrances and other Third Party interests (other
than existing Third Party license agreements entered into by Genaissance as set
forth in Exhibit 1.9);

 

(k)                                  Genaissance
and its Affiliates shall hold in confidence the identity of the consumers of
Consumer Products and Dual-Purpose Products and shall comply with applicable
laws, regulations and guidelines regarding confidentiality of patient records
and genetic information.  To the extent
applicable, Genaissance and its Affiliates shall comply with all applicable
requirements of the Health Insurance Portability and Accountability Act of 1996
and its related regulations (“HIPAA”), including any and all
requirements regarding the privacy and security of health information.  Genaissance and its Affiliates shall notify
Sciona orally and in writing within twenty-four (24) hours of its discovery of
any personal data in its possession that is improperly used, copied or removed
by anyone except to an authorized representative of Genaissance or Sciona or
their respective Affiliates, as the case may be.  Genaissance and its Affiliates shall cooperate with Sciona in
taking such steps as is deemed appropriate, to enjoin the misuse, regain
possession of the data, and otherwise protect each Parties’ rights and the
privacy of each consumer of Genetic Tests;

 

(l)                                     to
the extent applicable to Genaissance and its Affiliates, Genaissance and its
Affiliates shall make commercially reasonable efforts to identify and comply
with applicable laws, regulations and guidelines in the use and performance of
the Genetic Tests hereunder, including laws, regulations and guidelines
concerning genetic testing and shipping of biological samples; and

 

(m)                               during
the Access Period, Genaissance will not enter into any agreements, contracts or
other arrangements that would be inconsistent with its obligations under this
Agreement.

 

23

 

8.2                               Representations, Warranties and Covenants of
Sciona.  Sciona represents
and warrants to and covenants with Genaissance that:

 

(a)                                  Sciona
is a corporation duly organized, validly existing and in corporate good
standing under the laws of England;

 

(b)                                 Sciona
has the legal right, authority and power to enter into this Agreement, and to
extend the rights and licenses granted to Genaissance in this Agreement;

 

(c)                                  Sciona
has taken all necessary action to authorize the execution, delivery and
performance of this Agreement;

 

(d)                                 upon
the execution and delivery of this Agreement, this Agreement shall constitute a
valid and binding obligation of Sciona enforceable in accordance with its
terms, except as enforceability may be limited in the future by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors’ and contracting parties’ rights generally and except as
enforceability may be subject to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law);

 

(e)                                  the
performance of its obligations under this Agreement will not conflict with
Sciona’s charter documents or result in a breach of any agreements, contracts
or other arrangements to which it is a party;

 

(f)                                    all
of its employees, officers, consultants and advisors who are supporting the
performance of its obligations under this Agreement shall have executed or will
have executed agreements or have existing obligations under law requiring
assignment to Sciona of all intellectual property made during the course of and
as the result of their association with Sciona and obligating the individual to
maintain as confidential Sciona’s Confidential Information as well as
confidential information of a Third Party that Sciona may receive, to the
extent required to support Sciona’s obligations hereunder;

 

(g)                                 Sciona
and its Affiliates shall hold in confidence the identity of the consumers of
Consumer Products and Dual-Purpose Products and shall make commercially
reasonable efforts to identify and comply with (i) applicable laws, regulations
and guidelines regarding confidentiality of patient records and genetic
information, and (ii) all applicable requirements of HIPAA, including any and
all requirements regarding the privacy and security of health information.  Sciona and its Affiliates shall notify
Genaissance orally and in writing within twenty-four (24) hours of its
discovery of any personal data in its possession that is improperly used,
copied or removed by anyone except to an authorized representative of
Genaissance or Sciona or their respective Affiliates, as the case may be.  Sciona and its Affiliates shall cooperate
with Genaissance in taking such steps as is deemed appropriate, to enjoin the
misuse, regain possession of the data, and otherwise protect each Parties’
rights and the privacy of each consumer of Genetic Tests;

 

24

 

(h)                                 to
the extent applicable to Sciona and its Affiliates, Sciona and its Affiliates
shall make commercially reasonable efforts to identify and comply with all
applicable laws, regulations and guidelines in the manufacture, distribution,
marketing, sale, use, and performance of any Genetic Test, including laws,
regulations and guidelines concerning the proper acquisition of any diagnostic
or laboratory samples, informed consent requirements, genetic testing and
shipping of biological samples; and

 

(i)                                     during
the Access Period, Sciona will not enter into any agreements, contracts or
other arrangements that would be inconsistent with its obligations under this
Agreement.

 

8.3                               Limited Warranties relating to Performance of the DecoGen Informatics System.  Genaissance warrants that the DecoGen Informatics System delivered to
Sciona represents the latest version of the DecoGen
Informatics System that is available to licensees of the HAP Database.  Genaissance does not represent that the operations of the DecoGen Informatics System will be
trouble-free or that the DecoGen
Informatics System contains no errors. 
Genaissance’s only obligation to Sciona with respect to the DecoGen Informatics System will be to use
reasonable efforts consistent with its normal business practices to correct any
errors.

 

8.4                               WARRANTY DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO
THE HAP DATABASE, HAP MARKERS, DECOGEN INFORMATICS SYSTEM,
GENETIC TESTS, PATENT RIGHTS, GOODS, SERVICES OR OTHER SUBJECT MATTER OF THIS
AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE
FOREGOING.  IN ADDITION, SCIONA
ACKNOWLEDGES THAT THE HAP
DATABASE AND DECOGEN INFORMATICS SYSTEM MAY CONTAIN INFORMATION THE
ACQUISITION OR USE OF WHICH IS COVERED BY ONE OR MORE VALID PATENTS OF THIRD
PARTIES.  GENAISSANCE MAKES NO
REPRESENTATION OR WARRANTIES WITH RESPECT TO SCIONA’S USE OF THE INFORMATION TO
BE PROVIDED TO IT HEREUNDER.  GENAISSANCE
MAKES NO WARRANTY THAT THE HAP
DATABASE DOES NOT CONTAIN ERRORS OR THAT THE HAP
DATABASE CONTAINS ALL HAP MARKERS
THAT ARE ACTUALLY PRESENT BUT NOT DETECTED IN THE INDEX REPOSITORY.

 

8.5                               Interpretation

 

(a)                                  Awareness.  In this Section 8, the term “so far as
[a Party] is aware” or any similar or equivalent word shall be construed to
mean those matters within the actual knowledge of the senior management of the
relevant Party and those matters which would be apparent to such senior
managers upon carrying out commercially reasonable inquiries into such matters.

 

25

 

(b)                                 Actual knowledge.  In this Section 8, the term “actual
knowledge” shall be construed to mean those matters that are within the actual
knowledge of the senior management of the relevant Party without the
performance of any inquiry.

 

9.                                      INDEMNITY

 

9.1                               Sciona
Indemnity Obligations.  Sciona
agrees to defend, indemnify and hold Genaissance and its Affiliates and their
respective directors, officers, employees and agents harmless from all claims,
losses, damages, fees or expenses (including attorneys’ fees) relating to or
arising as a result of: (a) any actual or asserted violations of any applicable
law or regulation by Sciona or its Permitted Sciona Partners, including any
allegation or determination that any Genetic Tests (or any products or services
distributed in connection therewith) manufactured, marketed, distributed, sold
or performed hereunder are not in compliance with any applicable law or regulation;
(b) any unauthorized disclosure by Sciona or the Permitted Sciona Partners of
Third Party confidential information obtained by Sciona or the Permitted Sciona
Partners; (c) any claims for bodily injury, death or property damage, or
infringement of intellectual property rights attributable to the manufacture,
distribution, marketing, sale, use or performance of any Genetic Tests (or any
products or services distributed in connection therewith), provided that
indemnification for infringement of intellectual property rights shall not
include the products, materials (other than genes, polymorphisms or other
components of Genetic Tests that are specified by Sciona), tools, methodologies
and technologies (x) provided by, or (y) selected and used by, Genaissance in
performing any Collaboration Agreement or in providing services pursuant to any
agreement entered into pursuant to Sections 2.4 and 2.5; (d) any product recall
ordered by a governmental agency or required by a confirmed failure of any
product sold or performed in connection with this Agreement as reasonably
determined by the Parties hereto; (e) any claims by employees or contractors of
Sciona or its Affiliates for bodily injury, death or property damage arising
out of the performance by Sciona or its Permitted Sciona Partners of any
activities under this Agreement; (f) claims brought by Third Parties against
Genaissance and its Affiliates in respect of the negligence, recklessness or
intentional misconduct of Sciona or Permitted Sciona Partners in connection
with activities under this Agreement; or (g) a breach of any of the
representations, warranties or covenants made hereunder by Sciona.

 

9.2                               Genaissance Indemnity
Obligations. Genaissance
agrees to defend, indemnify and hold Sciona and its Affiliates and their
respective directors, officers, employees and agents harmless from all claims,
losses, damages, fees or expenses (including attorneys’ fees) relating to or
arising as a result of: (a) any unauthorized disclosure by Genaissance or its
Affiliates of Third Party confidential information obtained by Genaissance or
its Affiliates; (b) any claims by employees or contractors of Genaissance or
its Affiliates for bodily injury, death or property damage arising out of the
performance by Genaissance or its Affiliates of any activities under this
Agreement; (c) claims brought by Third Parties against Sciona, its Affiliates
or Permitted Sciona Partners in respect of the negligence, recklessness or
intentional misconduct of Genaissance in connection with its activities under
this Agreement, including the performance by Genaissance or its Affiliates of
Genetic Tests pursuant to Sections 2.4 and 2.5; (d) any claims brought by Third

 

26

 

Parties against Sciona or its Affiliates for bodily injury, death,
property damage or infringement of intellectual property rights by the
products, materials (other than genes, polymorphisms and other components of
Genetic Tests that are specified by Sciona), tools, methodologies and
technologies (x) provided by, or (y) selected and used by, Genaissance in
performing any Collaboration Agreement or in providing services pursuant to any
agreement entered into pursuant to Sections 2.4 and 2.5; or (e) a breach of any
of the representations, warranties or covenants made hereunder by Genaissance.

 

9.3                               Limitation
on Indemnity Obligations.  Neither
Party nor its respective Affiliates, employees or agents shall be entitled to
the indemnities set forth in Section 9.1 or Section 9.2 where the claim,
loss, damage or expense for which indemnification is sought was caused by a
grossly negligent or intentional act or omission by the other Party, its
Affiliates, directors, officers, employees or authorized agents.

 

9.4                               Procedure.  If the Party being indemnified hereunder
or its respective employees or agents (the “Indemnitee”)
intends to claim indemnification under this Article 9, the Indemnitee
shall promptly notify the other Party (the “Indemnitor”)
of any loss, claim, damage, liability or action in respect of which the
Indemnitee intends to claim such indemnification, and the Indemnitor shall
assume the defense thereof with counsel mutually satisfactory to the Parties; provided, however, that an Indemnitee
shall have the right to retain its own counsel, with the fees and expenses to
be paid by the Indemnitor, if representation of such Indemnitee by the counsel
retained by the Indemnitor would be inappropriate due to actual or potential
differing interests between such Indemnitee and any other Party represented by
such counsel in such proceedings.  The
indemnity agreement in this Article 9 shall not apply to amounts paid in
settlement of any loss, claim, damage, liability or action if such settlement
is effected without the consent of the Indemnitor, which consent shall not be
withheld or delayed unreasonably.  The failure to
deliver notice to the Indemnitor within a reasonable time after the
commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such Indemnitor of any liability to the Indemnitee under
this Article 9, but the omission so to deliver notice to the Indemnitor
will not relieve it of any liability that it may have to any Indemnitee
otherwise than under this Article 9.  The Indemnitee under this Article 9, its employees and
agents, shall cooperate fully with the Indemnitor and its legal representatives
in the investigation of any action, claim or liability covered by this
indemnification.  The Indemnitor shall
additionally be liable to pay the reasonable legal costs and attorneys’ fees
incurred by the Indemnitee in establishing its claim for indemnity if such
claim is upheld by a court of competent jurisdiction as successful or if such
claim is settled or as otherwise agreed by the Parties.

 

9.5                               Insurance.  Each Party shall maintain insurance,
including product liability insurance, with respect to its activities under
this Agreement.  Such insurance shall be
in such amounts and subject to such deductibles as the Parties may agree based
upon standards prevailing in the industry at the time; provided, that, as of the First Commercial
Sale of a Genetic Test, Sciona shall maintain a minimum of One Million Dollars
($1,000,000) in product liability insurance until the earlier of (a) closing of
the first financing round of Sciona after the Effective

 

27

 

Date or (b) June 30, 2004, by which date Sciona shall have
obtained and shall thereafter maintain an amount of product liability insurance
that is equal to Sciona’s projected Net Sales for each twelve (12) month period
covered by the insurance policy, provided
that Sciona shall not be required to maintain more than Ten Million
Dollars ($10,000,000) in product liability insurance.

 

10.                               TERM AND TERMINATION

 

10.1                        Access Period.

 

(a)                                  Unless this Agreement is sooner terminated in
accordance with the provisions of this Article 10, the “Access
Period” shall mean the period that commences on the Effective Date
and expires five (5) years from the Effective Date, subject to one (1) [**]
extension on terms mutually agreeable to Sciona and Genaissance,
including [**], which [**] shall be [**]. 
The Parties shall use reasonable endeavors to agree on the full and
final terms of such extension.

 

(b)                                 Upon
the expiration of the Access Period (or if earlier, termination of this
Agreement), Sciona shall return to Genaissance or destroy all copies (including
electronic copies) of the HAP Database
and DecoGen Informatics System,
including the deletion of all such copies from all computers on which such
database or software has been installed or transmitted.  Notwithstanding termination or expiration of
the Access Period, any license granted to Sciona pursuant to
Section 2.1(b) shall survive the termination or expiration of the Access
Period.

 

10.2                        Term of Agreement.  This Agreement shall become effective as of the
Effective Date and except as otherwise provided in Sections 10.2 or 10.4, shall
remain in effect until the later of: 
(i) the expiration of all obligations to make payments set forth in
Articles 4 and 5, and (ii) the expiration of all licenses and other rights
granted in Article 2.

 

10.3                        Termination by Either Party.  This Agreement may be terminated immediately upon written notice to the other Party upon the
occurrence of any of the following events:

 

(a)                                  the
other Party commits a material breach of this Agreement (other than: (i) in
respect of a failure by Sciona to make a payment pursuant to Section 5.2
or Section 5.3, in which event the right of Genaissance to terminate this
Agreement is as set forth in Section 10.4(a); and (ii) in respect of a
failure by Sciona to make any Minimum Annual Payment, in which event the right
of Genaissance to terminate this Agreement is as set forth in
Section 10.4(b)); and the breaching Party fails to remedy such breach
within [**] days after written notice thereof by the non-breaching Party; or

 

(b)                                 the
other Party ceases to do business, or otherwise terminates its business
operations; or

 

(c)                                  the
other Party enters into and/or itself applies for, and/or calls meetings of
members and/or creditors with a view to, one or more of a moratorium,
administration, liquidation (of any kind, including provisional), or
composition and/or arrangement (whether

 

28

 

under deed or otherwise) with creditors, and/or have any of its
property subjected to one or more of appointment of a receiver (of any kind),
enforcement of security, distress, or execution of a judgment (in each case to
include similar events under the laws of the applicable country); or

 

(d)                                 the
other Party commits fraud or any unlawful act in connection with or affecting
this Agreement.

 

10.4                        Termination by Genaissance.  In addition to Genaissance’s rights under
Section 10.2, Genaissance may terminate this Agreement immediately upon
written notice to Sciona upon the occurrence of any of the following events:

 

(a)                                  after
[**] days’ written notice from Genaissance of termination pursuant to this
section 10.4(a), Sciona fails to make any undisputed payment due or owing
pursuant to Section 5.2 or Section 5.3; or

 

(b)                                 Sciona
fails to pay Genaissance at least [**] percent ([**]%) of the Minimum Annual
Payments in each of [**] years and Genaissance is in compliance, in all
material respects, with the terms and conditions of Section 2.1(a), provided, that if Genaissance exercises its rights to terminate pursuant
to this clause 10.4(b), Genaissance shall offer to sell its Shares to the other
shareholders of Sciona for £[**] in aggregate for all such Shares pursuant to
the terms of the articles of association of Sciona; or

 

(c)                                  after
[**] days’ written notice from Genaissance, Sciona fails to remedy any material
breach of the Investment Agreement (save where the breach concerned is a breach
of the warranty provisions set out in clause 7 and/or schedule 1, of the
Investment Agreement, in which event Genaissance shall have no right to
terminate this Agreement); or

 

(d)                                 Sciona
and its Affiliates fail to obtain or achieve cumulative combined sales revenues
and Third Party financing (equity or debt) of at least [**] U.S. dollars
($[**]) within [**] months of the Effective Date; provided, that if
Genaissance exercises its rights to terminate pursuant to this clause 10.4(d),
Genaissance shall offer to sell its Shares to the other shareholders of Sciona
for £[**] in aggregate for all such Shares pursuant to the terms of the
articles of association of Sciona.  For the avoidance of doubt, the amount of financing or sales
revenues obtained by Sciona before the Effective Date shall not be applicable
to this Section 10.4(d).

 

10.5                        Effect of
Termination; Survival.

 

(a)                                  Termination of this Agreement
for any reason or expiration of this Agreement shall be without prejudice to
any rights or obligations that shall have accrued to the benefit of either
Party prior to such termination or expiration, including Sciona’s obligation to
pay Royalties, Service Fees and Minimum Annual Payments.  Such termination or expiration shall not
relieve either Party from obligations which are expressly indicated to survive
termination or expiration of this Agreement. 
The remedies set forth in this Article 10 are not exclusive and are

 

29

 

without prejudice to any other rights conferred on the non-breaching Party
by this Agreement and any other remedies available to it by law or in equity.

 

(b)                                 The
following sections of this Agreement shall survive any termination or
expiration of this Agreement: Section 3.3,
5.5 (in respect of matters, facts and circumstances arising only during the
term of this Agreement), 5.7, 5.8, 6.1 and 10.5 and Articles 7, 9 (in respect
of matters, facts and circumstances arising only during the term of this
Agreement) and 11.

 

11.                               MISCELLANEOUS

 

11.1                        Force Majeure.  Neither Party shall be held liable or responsible to
the other Party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in fulfilling or performing any term of this
Agreement when such failure or delay is caused by or results from causes beyond
the reasonable control of the affected Party, including fire, floods,
embargoes, war, acts of war (whether war is declared or not), insurrections,
riots, civil commotions, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority or the
other Party; provided, however,
that the Party so affected shall use reasonable commercial efforts to avoid or
remove such causes of nonperformance, and shall continue performance hereunder
with reasonable dispatch whenever such causes are removed.  Either Party shall provide the other Party
with prompt written notice of any delay or failure to perform that occurs by
reason of force majeure.  The Parties
shall mutually seek a resolution of the delay or the failure to perform as
noted above.

 

11.2                        Consequential Damages.  Neither Party shall be liable under this
Agreement for special, incidental or consequential damages or for loss of
profit or lost revenue, even if advised of the possibility of such damages.  NEITHER PARTY HERETO WILL BE LIABLE FOR
SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS
AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS
ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY
NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A MATERIAL BREACH OF THE
CONFIDENTIALITY AND USE OBLIGATIONS IN ARTICLE 7.  NOTHING IN THIS SECTION 11.2 IS
INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF
EITHER PARTY.

 

11.3                        Assignment.  Neither this Agreement nor any of the rights
or obligations hereunder may be assigned by either Party without the prior
written consent of the other Party, such consent not to be unreasonably
withheld.  Any purported assignment or
transfer in violation of the preceding sentence shall be void.  Any permitted assignee or transferee shall
assume all obligations of its assignor under this Agreement.  No assignment or transfer shall relieve
either Party of responsibility for the performance of any accrued obligation
that such Party then has hereunder.

 

30

 

11.4                        Severability.  In the event that any provision of this Agreement is
held by a court of competent jurisdiction to be unenforceable because it is
invalid or in conflict with any law of the relevant jurisdiction, the validity
of the remaining provisions shall not be affected and the rights and
obligations of the Parties shall be construed and enforced as if the Agreement
did not contain the particular provisions held to be unenforceable, provided
that the Parties shall negotiate in good faith a modification of this Agreement
with a view to revising this Agreement in a manner which reflects, as closely
as is reasonably practicable, the commercial terms of this Agreement as
originally signed.

 

11.5                        Notices. 
Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the Parties hereto to the other
shall be in writing, delivered personally or by facsimile (and promptly
confirmed by telephone, personal delivery or courier) or courier, postage
prepaid (where applicable), addressed to such other Party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor and shall be effective upon receipt by
the addressee. 

 

	
  If to Genaissance:

  	
   

  	
  Genaissance Pharmaceuticals, Inc.

  
	
   

  	
   

  	
  Five Science Park

  
	
   

  	
   

  	
  New Haven, Connecticut  06511

  
	
   

  	
   

  	
  Attention: Chief Executive Officer

  
	
   

  	
   

  	
  Telephone: (203) 773-1450

  
	
   

  	
   

  	
  Facsimile: (203) 562-9377

  
	
   

  	
   

  	
   

  
	
  If to Sciona:

  	
   

  	
  Sciona Limited

  
	
   

  	
   

  	
  25 Broadmarsh Business and Innovation Centre

  
	
   

  	
   

  	
  Harts Farm Way

  
	
   

  	
   

  	
  Havant Hampshire

  
	
   

  	
   

  	
  P09 HIS

  
	
   

  	
   

  	
  United Kingdom

  
	
   

  	
   

  	
  Attention:

  
	
   

  	
   

  	
  Telephone:

  
	
   

  	
   

  	
  Facsimile:

  

 

11.6                        Applicable Law.  This Agreement shall be governed by and
construed in accordance with the laws of the State of Connecticut, without
giving effect to the choice of laws provisions thereof.

 

11.7                        Dispute Resolution.

 

(a)                                  The
Parties hereby agree that they will attempt in good faith to resolve any
controversy or claim arising out of or relating to this Agreement promptly by
negotiations.  If a controversy or claim
should arise hereunder, the matter shall be referred to an individual 

 

31

 

designated by the Chief Executive Officer (or the equivalent position)
of Genaissance and an individual designated by the Chief Executive Officer (or
the equivalent position) of Sciona (the “Representatives”).  If the matter has not been resolved within
[**] days of the first meeting of the Representatives of the Parties (which
period may be extended by mutual agreement) concerning such matter, subject to
rights to injunctive relief and specific performance, and unless otherwise
specifically provided for herein, any controversy or claim arising out of or
relating to this Agreement, or the breach thereof, will be settled as set forth
in Section 11.7(b).

 

(b)                                 All
disputes arising in connection with this Agreement shall be finally settled by
binding arbitration conducted in New York, New York under the Commercial
Arbitration Rules of the American Arbitration Association by a single
arbitrator appointed in accordance with said Rules.  Notwithstanding the above, either Party has the right to bring
suit in a court of competent jurisdiction against the other Party for (i) any
breach of such other Party’s duties of confidentiality pursuant to
Article 7 of this Agreement and (ii) any infringement of its own
proprietary rights by the other Party. 
Judgment upon the arbitrator’s award may be entered in any court of
competent jurisdiction.  The award of
the arbitrator may include compensatory damages against either Party, but under
no circumstances will the arbitrator be authorized to, nor shall he, award
punitive damages or multiple damages against either Party.  The Parties agree not to institute any
litigation or proceedings against each other in connection with this Agreement
except as provided in this Section 11.7.

 

11.8                        Publicity. 
Except as required by law, Genaissance and Sciona each agree
not to disclose the existence or any terms or conditions of this Agreement to
any Third Party without consulting the other Party prior to such
disclosure.  Notwithstanding the
foregoing, Genaissance and Sciona agree that a press release will be issued
promptly after execution of this Agreement in the form to be attached as Exhibit
11.8 and information contained in such press release can be used as a
routine reference in the usual course of business to describe the terms of this
transaction, and Genaissance and Sciona may disclose such information without
consulting the other Party.  The Parties
may thereafter from time to time mutually agree on revisions to material to be
used as a routine reference, which revisions shall be submitted by one Party
for the review and approval of the other Party at least [**] days prior to the
anticipated use or disclosure of the revised material, such approval not to be
unreasonably withheld.

 

11.9                        Headings.  The captions to the several Articles and Sections
hereof are not a part of this Agreement, but are merely guides or labels to
assist in locating and reading the several Articles and Sections hereof.

 

11.10                 No Partnership.  It is expressly agreed that the relationship between
Genaissance and Sciona shall not constitute a partnership, joint venture or
agency.  Neither Genaissance nor Sciona
nor their Affiliates shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall
be binding on the other, without the prior consent of the other Party to do so.

 

32

 

11.11                 Exports.  The Parties acknowledge that the export of technical data,
materials or products is subject to the exporting Party receiving any necessary
export licenses and that the Parties cannot be responsible for any delays
attributable to export controls which are beyond the reasonable control of
either Party.  Genaissance and Sciona
agree not to export or re-export, directly or indirectly, any information,
technical data, the direct product of such data, samples or equipment received
or generated under this Agreement in violation of any applicable export control
laws or governmental regulations. 
Genaissance and Sciona agree to obtain similar covenants from their
Affiliates, licensees, sublicensees and contractors with respect to the subject
matter of this Section.

 

11.12                 Waiver.  The waiver by either Party of a breach or default of any
provision of this Agreement by the other Party shall not be construed as a
waiver of any succeeding breach of the same or any other provision, nor shall
any delay or omission on the part of either Party to exercise or avail itself
of any right, power or privilege that it has or may have hereunder operate as a
waiver of any right, power or privilege by such Party.

 

11.13                 Entire Agreement.  This Agreement and the Investment Agreement constitute
the entire agreement between the Parties with respect to its subject matter and
supersedes all previous written or oral representations, agreements and
understandings between the Parties, including the confidentiality agreement
between the Parties dated February 1, 2002.  This Agreement may be amended, or any term hereof modified, only
by a written instrument duly executed by both Parties hereto.

 

11.14                 Counterparts.  This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

 [THE NEXT
PAGE IS THE SIGNATURE PAGE]

 

33

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
date of this Agreement.

 

 

	
  GENAISSANCE
  PHARMACEUTICALS, INC.

  	
  SCIONA LIMITED

  
	
   

  	
   

  
	
   

  	
   

  
	
  By

  	
   /s/ Kevin Rakin

  	
   

  	
  By

  	
   /s/ Christopher J. Martin

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title 

  	
  President & Chief Executive Officer

  	
   

  	
  Title 

  	
  Chief Executive Officer

  	
   

  
								

 

34

 

Exhibit 1.7

 

1.                                       Description of
the DecoGen®
Informatics System

 

DecoGen® Browser Software

 

•                       Description:  The DecoGen
Browser software allows a user to browse genes, polymorphism data and clinical
data; perform association analysis; calculate linkage disequilibrium; view
Haplotype phylogenies; create and save projects based on clinical cohorts.  The browser only operates on genes for which
haplotypes have been built.  Statistical
analyses are run using SAS.  The gene
structure, polymorphisms and haplotypes must be in the HAP Database for each gene to be
viewed.  DecoGen® DataManager software and gene structures
are required to load customer-created polymorphisms or haplotypes.  Additional gene structures may be added to
the HAP Database via purchase of
additional software or custom services from Genaissance.

 

•                       Sciona
provides:  Hardware for database
server, file server and desktop clients; appropriate Oracle license, database
administrator support for (DBA) for installation and data updates; a server and
license for SAS.

 

DecoGen® DataManager Software

 

•                       Description:  The DecoGen
DataManager software allows a user to browse genes and polymorphism data, in
more detail than provided by the DecoGen
Browser software, but does not include any clinical analysis tools.  DecoGen
DataManager software requires that the gene structure, polymorphisms and
genotypes be in the HAP Database
for information on each gene to be viewed, but does not require the presence of
haplotypes.  DecoGen DataManager software provides full access to the HAP Database Schema and has tools for
importing a variety of data including polymorphisms, genotypes and haplotypes
for any gene whose structure is in the HAP
Database.  Polymorphism and other types
of data in the HAP Database may
also be exported using DecoGen
DataManager.  This software does not
include any clinical analysis tools. 
Additional gene structures may be added to the HAP Database via purchase of additional
software or custom services from Genaissance.

 

•                       Sciona
provides: Hardware for database server, file server and desktop clients;
appropriate Oracle license, database administrator support for (DBA) for
installation and data updates.

 

2.               Technical Specifications for the HAP Database and DecoGen Informatics System

 

2.1                               HAP Database

 

Installation and Operating
Requirements

 

The HAPTM
Database is an Oracle database which requires the following minimum
configuration:

 

 

	
  2.1.1

  	
   

  	
  Database Configuration

  
	
   

  	
   

  	
  Software:

  	
  Oracle [**] Edition.

  
	
   

  	
   

  	
   

  
	
  2.1.2

  	
   

  	
  Hardware Requirements

  
	
   

  	
   

  	
  Server:

  	
  [**]

  
	
   

  	
   

  	
  Memory:

  	
  [**] GB, depending on number of users.

  
	
   

  	
   

  	
  SWAP Space:

  	
  [**].

  
	
   

  	
   

  	
  CD_ROM Device:

  	
  [**]

  
	
   

  	
   

  	
  CPU:

  	
  [**]

  
	
   

  	
   

  	
  Tape device:

  	
  [**]

  
	
   

  	
   

  	
   

  
	
  2.1.3

  	
   

  	
  Disk Space Requirements:

  
	
   

  	
   

  	
  Oracle Software:

  	
  ~ [**] GB ([**] Edition)

  
	
   

  	
   

  	
  Database:

  	
  [**].

  
	
   

  	
   

  	
   

  	
  [**]

  
	
   

  	
   

  	
   

  
	
  2.1.4

  	
   

  	
  Operating System Software Requirements

  
	
   

  	
   

  	
  Operating System:

  	
  [**].

  
	
   

  	
   

  	
   

  	
  [**].

  
	
   

  	
   

  	
   

  	
  [**].

  
					

 

2.2                               The DecoGen Informatics
System

 

Cross-platform application, built on top of the HAP Database.  The client application resides on a shared
drive and is invoked by running a batch initialization file from the client
machine.

 

Installation and Operating
Requirements 

 

2.2.1                        DecoGen® Client

 

Minimum recommended client configuration:

 

•                                          CPU:
[**];

•                                          Memory:
[**];

•                                          Hard
disk: [**];

•                                          Operating
System: Window [**].

•                                          Java Runtime version: [**]

 

2.2.2                        SAS Server

 

•                  SAS Software 8.2
release on NT or Windows 2000 server (Service Pack 2)

•                  [**] memory

•                  [**] Drives for
OS and Data

 

2

 

•                  [**]

•                  CD-Rom

•                  SAS Software 8.2
required components must include SAS/BASE, SAS/STAT, SAS/CONNECT, SAS/IntrNet,
and SAS/Graph.

 

3

 

Exhibit 1.9

 

Third Party Licenses to HAP Technology

 

Strength License Agreement with AstraZeneca UK Limited, dated
September 5, 2003

 

Technology and Database License Agreement with Millennium
Pharmaceuticals, Inc., dated January 7, 2003

 

Research Collaboration and License Agreement with Bayer AG and Bayer
Healthcare LLC, dated January 15, 2003

 

License Agreement with Wayne State University, dated March 11,
2003

 

Agreement with Pharmacia & Upjohn Company, dated December 13,
2002

 

MednosticsTM Collaboration and License Agreement with Biogen, Inc.,
dated January 31, 2002

 

HAP Focus Trial License Agreement with Biogen, Inc., dated
December 21, 2001

 

HAP Focus Trial License Agreement with AstraZeneca, dated
November 29, 2001

 

Agreement with Pfizer Inc., dated August 31, 2001, as amended
May 16, 2002 and February 6, 2003

 

HAP2000 Agreement
with Janssen Research Foundation, dated November 22, 2000, as amended
November 22, 2002

 

Collaboration Agreement with Gene Logic, Inc., dated June 28, 2000

 

 

Exhibit 1.17

 

[**]

 

 

Schedule 2.4

 

Third Party Arrangements for Genetic Tests

 

 

[**]

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]